false Q2--12-31 0000903129 http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember July 31, 2025 http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#ForeignCurrencyTransactionGainLossBeforeTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#OtherComprehensiveIncomeLossNetOfTax http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#InterestIncomeExpenseNet http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember http://fasb.org/us-gaap/2023#ProductMember 0000903129 country:US 2023-01-01 2023-06-30 0000903129 thrm:OtherCountriesMember 2023-04-01 2023-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-04-01 2022-06-30 0000903129 country:KR 2023-04-01 2023-06-30 0000903129 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2023-01-01 2023-06-30 0000903129 country:FI 2022-04-01 2022-06-30 0000903129 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000903129 thrm:BatteryPerformanceSolutionsBPSMember thrm:AutomotiveSegmentsMember 2022-01-01 2022-06-30 0000903129 2022-06-30 0000903129 thrm:DachengMember 2023-01-01 2023-06-30 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2022-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2023-03-31 0000903129 us-gaap:SoftwareDevelopmentMember 2023-06-30 0000903129 thrm:InventoryMember 2023-01-01 2023-06-30 0000903129 thrm:UnitedStateAndEuroDenominatedRevolvingNoteMember 2023-06-30 0000903129 thrm:MedicalSegmentsMember 2023-04-01 2023-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalMember 2023-04-01 2023-06-30 0000903129 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000903129 country:JP 2023-04-01 2023-06-30 0000903129 thrm:AlfmeierMember 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2022-03-31 0000903129 country:JP 2022-04-01 2022-06-30 0000903129 us-gaap:CommodityContractMember 2022-04-01 2022-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember 2023-06-30 0000903129 us-gaap:RetainedEarningsMember 2022-06-30 0000903129 us-gaap:InterestRateSwapMember 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0000903129 country:DE 2023-04-01 2023-06-30 0000903129 us-gaap:PropertyPlantAndEquipmentMember 2022-01-01 2022-12-31 0000903129 us-gaap:InterestRateContractMember us-gaap:InterestIncomeMember us-gaap:NondesignatedMember 2022-04-01 2022-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2022-12-31 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2022-04-01 2022-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2023-04-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000903129 thrm:EmployeeSeparationCostsMember 2023-03-31 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-01-01 2022-06-30 0000903129 us-gaap:CustomerRelationshipsMember 2023-06-30 0000903129 country:DE 2022-01-01 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2022-01-01 2022-06-30 0000903129 2022-12-31 0000903129 us-gaap:InterestRateSwapMember 2023-04-01 2023-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2022-04-01 2022-06-30 0000903129 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000903129 thrm:AutomotiveSegmentsMember thrm:LumbarAndMassageComfortSolutionsMember 2023-01-01 2023-06-30 0000903129 thrm:OtherLoansMember srt:MinimumMember 2022-12-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-06-30 0000903129 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0000903129 us-gaap:CustomerRelationshipsMember thrm:DachengMember 2022-07-13 2022-07-13 0000903129 thrm:FloatingToFixedInterestRateSwapMember 2023-01-01 2023-06-30 0000903129 us-gaap:RetainedEarningsMember 2022-03-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000903129 2023-03-31 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember thrm:DachengMember 2022-07-13 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2022-04-01 2022-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2023-04-01 2023-06-30 0000903129 country:SK 2023-01-01 2023-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2023-01-01 2023-06-30 0000903129 country:CN 2022-01-01 2022-06-30 0000903129 srt:MinimumMember thrm:SecondAmendedAndRestatedCreditAgreementMember thrm:TermSofrRateLoansMember 2023-01-01 2023-06-30 0000903129 us-gaap:InterestRateSwapMember 2022-04-01 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2022-04-01 2022-06-30 0000903129 us-gaap:CorporateMember 2022-04-01 2022-06-30 0000903129 country:MX 2022-01-01 2022-06-30 0000903129 us-gaap:CorporateMember 2023-01-01 2023-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2022-03-31 0000903129 thrm:AutomotiveSegmentsMember thrm:ValveSystemMember 2023-04-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000903129 us-gaap:IndefinitelivedIntangibleAssetsMember 2022-01-01 2022-12-31 0000903129 thrm:OtherDebtMember 2023-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2023-04-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2023-04-01 2023-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2022-04-01 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2023-04-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2023-01-01 2023-06-30 0000903129 us-gaap:RelatedPartyMember 2023-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2022-01-01 2022-06-30 0000903129 us-gaap:RetainedEarningsMember 2023-06-30 0000903129 country:RO 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2023-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:CommonStockMember 2022-06-30 0000903129 thrm:AlfmeierMember srt:ScenarioPreviouslyReportedMember 2022-08-01 2022-08-01 0000903129 thrm:DachengMember 2023-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000903129 thrm:AlfmeierMember 2022-08-01 2022-08-01 0000903129 srt:MinimumMember thrm:SemiconductorChipsMember 2023-01-01 2023-06-30 0000903129 us-gaap:RelatedPartyMember 2022-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2023-06-30 0000903129 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2023-06-30 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2023-06-30 0000903129 thrm:AlfmeierMember 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalMember 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2022-04-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2022-04-01 2022-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember thrm:EmployeeSeparationCostsMember 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2022-01-01 2022-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:FairValueMeasurementsNonrecurringMember 2022-12-31 0000903129 country:MX 2023-04-01 2023-06-30 0000903129 thrm:SecondAmendedAndRestatedCreditAgreementMember 2022-06-10 2022-06-10 0000903129 us-gaap:CommodityContractMember 2022-01-01 2022-06-30 0000903129 thrm:DachengMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-07-13 2022-07-13 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2023-01-01 2023-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:CommodityContractMember 2023-04-01 2023-06-30 0000903129 us-gaap:FederalFundsEffectiveSwapRateMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember 2022-12-31 0000903129 thrm:DachengMember 2022-07-13 0000903129 2023-01-01 2023-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000903129 thrm:AutomotiveSegmentsMember 2022-01-01 2022-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2022-04-01 2022-06-30 0000903129 thrm:UnitedStateRevolvingNoteMember 2022-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalMember 2022-12-31 0000903129 thrm:EntitiesOwnershipInterestMember 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember 2023-01-01 2023-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2022-04-01 2022-06-30 0000903129 us-gaap:ForeignExchangeContractMember 2023-04-01 2023-06-30 0000903129 2021-12-31 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentMember 2023-06-30 0000903129 us-gaap:OperatingSegmentsMember 2023-01-01 2023-06-30 0000903129 2023-07-26 0000903129 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2022-04-01 2022-06-30 0000903129 thrm:MedicalSegmentsMember 2023-01-01 2023-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember thrm:EmployeeSeparationCostsMember 2023-04-01 2023-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ForeignExchangeContractMember 2022-12-31 0000903129 thrm:AutomotiveSegmentsMember 2023-04-01 2023-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2022-01-01 2022-06-30 0000903129 us-gaap:RetainedEarningsMember 2021-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2023-01-01 2023-06-30 0000903129 thrm:OtherCountriesMember 2022-04-01 2022-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-04-01 2023-06-30 0000903129 us-gaap:CommonStockMember 2021-12-31 0000903129 country:SK 2022-04-01 2022-06-30 0000903129 country:DE 2022-04-01 2022-06-30 0000903129 thrm:AlfmeierMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-08-01 2022-08-01 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2023-04-01 2023-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2023-04-01 2023-06-30 0000903129 us-gaap:CustomerRelationshipsMember thrm:AlfmeierMember 2022-08-01 2022-08-01 0000903129 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0000903129 us-gaap:TechnologyBasedIntangibleAssetsMember 2023-06-30 0000903129 2022-04-01 2022-06-30 0000903129 us-gaap:InterestRateContractMember us-gaap:InterestIncomeMember us-gaap:NondesignatedMember 2023-01-01 2023-06-30 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2023-01-01 2023-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:SwingLineLoansMember 2022-06-10 0000903129 us-gaap:InterestRateSwapMember 2023-01-01 2023-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2022-12-31 0000903129 thrm:AlfmeierMember 2023-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2021-12-31 0000903129 srt:ScenarioPreviouslyReportedMember thrm:DachengMember 2022-07-13 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2023-01-01 2023-06-30 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2023-06-30 0000903129 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000903129 country:CZ 2022-01-01 2022-06-30 0000903129 country:CZ 2022-04-01 2022-06-30 0000903129 us-gaap:NonUsMember 2023-01-01 2023-06-30 0000903129 thrm:AlfmeierMember 2022-08-01 0000903129 thrm:BaseRateLoansMember srt:MinimumMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2023-01-01 2023-06-30 0000903129 country:KR 2023-01-01 2023-06-30 0000903129 thrm:DachengMember srt:RestatementAdjustmentMember 2022-07-13 0000903129 srt:MinimumMember 2023-01-01 2023-06-30 0000903129 thrm:BatteryPerformanceSolutionsBPSMember thrm:AutomotiveSegmentsMember 2023-04-01 2023-06-30 0000903129 thrm:AlfmeierMember srt:RestatementAdjustmentMember 2022-08-01 2022-08-01 0000903129 us-gaap:InterestRateContractMember us-gaap:InterestIncomeMember us-gaap:NondesignatedMember 2023-04-01 2023-06-30 0000903129 us-gaap:InProcessResearchAndDevelopmentMember 2022-12-31 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2022-01-01 2022-06-30 0000903129 us-gaap:CustomerRelationshipsMember thrm:AlfmeierMember 2022-08-01 0000903129 thrm:AutomotiveSegmentsMember thrm:ValveSystemMember 2023-01-01 2023-06-30 0000903129 country:KR 2022-04-01 2022-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2023-04-01 2023-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2023-01-01 2023-03-31 0000903129 thrm:AlfmeierMember us-gaap:TechnologyBasedIntangibleAssetsMember 2022-08-01 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000903129 thrm:MedicalSegmentsMember thrm:DachengMember 2023-01-01 2023-06-30 0000903129 thrm:AlfmeierMember srt:RestatementAdjustmentMember 2022-08-01 0000903129 thrm:AccumulatedCommodityHedgeDerivativesAdjustmentMember 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000903129 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2023-01-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember 2022-04-01 2022-06-30 0000903129 country:US 2022-04-01 2022-06-30 0000903129 2022-03-31 0000903129 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:NondesignatedMember 2022-12-31 0000903129 country:RO 2022-04-01 2022-06-30 0000903129 thrm:FloatingToFixedInterestRateSwapMember 2023-06-30 0000903129 2023-04-01 2023-06-30 0000903129 us-gaap:TradeNamesMember 2022-12-31 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2023-04-01 2023-06-30 0000903129 thrm:FinanceLeasesMember 2023-06-30 0000903129 thrm:MedicalSegmentsMember thrm:DachengMember 2023-04-01 2023-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember thrm:EmployeeSeparationCostsMember 2022-04-01 2022-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2021-12-31 0000903129 country:JP 2023-01-01 2023-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:LettersOfCreditMember 2022-12-31 0000903129 us-gaap:ForeignExchangeContractMember 2022-01-01 2022-06-30 0000903129 us-gaap:CommodityContractMember 2023-04-01 2023-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentMember 2023-01-01 2023-06-30 0000903129 2022-01-01 2022-03-31 0000903129 country:MX 2022-04-01 2022-06-30 0000903129 thrm:OtherCountriesMember 2022-01-01 2022-06-30 0000903129 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 us-gaap:StandbyLettersOfCreditMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2022-06-10 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000903129 us-gaap:RetainedEarningsMember 2023-03-31 0000903129 us-gaap:CorporateMember 2022-01-01 2022-06-30 0000903129 country:FI 2023-01-01 2023-06-30 0000903129 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SteeringWheelHeatersMember 2023-01-01 2023-06-30 0000903129 thrm:OtherRestructuringActivitiesMember 2023-04-01 2023-06-30 0000903129 country:US 2023-04-01 2023-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2022-04-01 2022-06-30 0000903129 thrm:OtherCountriesMember 2023-01-01 2023-06-30 0000903129 us-gaap:NonUsMember 2023-04-01 2023-06-30 0000903129 thrm:MedicalSegmentsMember 2022-04-01 2022-06-30 0000903129 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0000903129 us-gaap:CommonStockMember 2022-12-31 0000903129 country:US 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-12-31 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2022-06-10 2022-06-10 0000903129 us-gaap:NonUsMember 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember us-gaap:CorporateMember 2023-04-01 2023-06-30 0000903129 us-gaap:NonUsMember 2022-04-01 2022-06-30 0000903129 us-gaap:CustomerRelationshipsMember 2022-12-31 0000903129 us-gaap:OtherRestructuringMember 2023-04-01 2023-06-30 0000903129 thrm:DachengMember 2022-07-13 2022-07-13 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2022-04-01 2022-06-30 0000903129 country:MX 2023-01-01 2023-06-30 0000903129 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2022-03-31 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-01-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2023-01-01 2023-06-30 0000903129 srt:MaximumMember thrm:SemiconductorChipsMember 2023-01-01 2023-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignCurrencyGainLossMember us-gaap:ForeignExchangeContractMember 2022-01-01 2022-06-30 0000903129 thrm:FinanceLeasesMember 2022-12-31 0000903129 us-gaap:InterestRateContractMember us-gaap:InterestIncomeMember us-gaap:NondesignatedMember 2022-01-01 2022-06-30 0000903129 us-gaap:OtherRestructuringMember 2023-01-01 2023-03-31 0000903129 thrm:OtherAutomotiveMember thrm:AutomotiveSegmentsMember 2022-04-01 2022-06-30 0000903129 thrm:AlfmeierMember srt:ScenarioPreviouslyReportedMember 2022-08-01 0000903129 thrm:InventoryMember 2022-01-01 2022-12-31 0000903129 thrm:ManufacturingFootprintRationalizationMember thrm:EmployeeSeparationCostsMember 2023-01-01 2023-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:CommodityContractMember 2022-04-01 2022-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember 2022-06-10 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:CommodityContractMember 2022-01-01 2022-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2022-12-31 0000903129 country:JP 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember 2022-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000903129 us-gaap:SoftwareDevelopmentMember 2022-12-31 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2021-12-31 0000903129 country:FI 2022-01-01 2022-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2023-06-30 0000903129 us-gaap:RetainedEarningsMember 2022-12-31 0000903129 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentsMember 2023-04-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2023-01-01 2023-06-30 0000903129 us-gaap:CommonStockMember 2023-06-30 0000903129 thrm:BaseRateLoansMember srt:MaximumMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember 2023-06-30 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:ForeignExchangeContractMember 2022-01-01 2022-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember srt:MaximumMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2022-06-10 0000903129 country:DE 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000903129 thrm:ManufacturingFootprintRationalizationMember 2023-01-01 2023-06-30 0000903129 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember 2022-01-01 2022-06-30 0000903129 us-gaap:ForeignExchangeContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember 2023-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:MedicalMember 2023-06-30 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2023-04-01 2023-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2022-01-01 2022-06-30 0000903129 thrm:EmployeeSeparationCostsMember 2023-04-01 2023-06-30 0000903129 thrm:UnitedStateRevolvingNoteMember 2023-06-30 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000903129 2023-06-30 0000903129 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2023-04-01 2023-06-30 0000903129 thrm:OtherLoansMember srt:MaximumMember 2022-12-31 0000903129 us-gaap:CommonStockMember 2022-03-31 0000903129 srt:ScenarioPreviouslyReportedMember thrm:DachengMember 2022-07-13 2022-07-13 0000903129 us-gaap:OtherComprehensiveIncomeMember us-gaap:CommodityContractMember 2023-01-01 2023-06-30 0000903129 thrm:IndustrialSegmentsMember thrm:MedicalMember 2022-04-01 2022-06-30 0000903129 country:CN 2023-04-01 2023-06-30 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember 2023-04-01 2023-06-30 0000903129 2022-01-01 2022-06-30 0000903129 country:CZ 2023-04-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2022-01-01 2022-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember srt:MinimumMember thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-01-01 2023-06-30 0000903129 thrm:SemiconductorChipsMember 2023-01-01 2023-06-30 0000903129 us-gaap:CommonStockMember 2023-03-31 0000903129 country:CN 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-03-31 0000903129 thrm:TwoThousandTwentyStockRepurchaseProgramMember 2020-01-01 2020-12-31 0000903129 country:SK 2023-04-01 2023-06-30 0000903129 us-gaap:TradeNamesMember thrm:DachengMember 2022-07-13 0000903129 us-gaap:NondesignatedMember us-gaap:ForeignExchangeContractMember us-gaap:ForeignCurrencyGainLossMember 2023-04-01 2023-06-30 0000903129 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0000903129 srt:MaximumMember thrm:TwoThousandTwentyStockRepurchaseProgramMember 2020-12-31 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:AutomotiveCablesMember 2022-04-01 2022-06-30 0000903129 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateContractMember us-gaap:NondesignatedMember us-gaap:OtherCurrentAssetsMember 2023-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2022-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:RevolvingCreditFacilityMember thrm:LettersOfCreditMember 2023-06-30 0000903129 thrm:ManufacturingFootprintRationalizationMember 2022-04-01 2022-06-30 0000903129 thrm:AccumulatedForeignCurrencyHedgeDerivativesMember 2022-01-01 2022-06-30 0000903129 thrm:MedicalSegmentsMember 2022-01-01 2022-06-30 0000903129 us-gaap:CustomerRelationshipsMember thrm:DachengMember 2022-07-13 0000903129 country:RO 2022-01-01 2022-06-30 0000903129 us-gaap:ForeignExchangeContractMember 2022-04-01 2022-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:ForeignExchangeContractMember 2022-01-01 2022-06-30 0000903129 country:CN 2022-04-01 2022-06-30 0000903129 thrm:BatteryPerformanceSolutionsBPSMember thrm:AutomotiveSegmentsMember 2022-04-01 2022-06-30 0000903129 thrm:InventoryMember 2023-04-01 2023-06-30 0000903129 country:SK 2022-01-01 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2022-01-01 2022-06-30 0000903129 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2023-06-30 0000903129 country:KR 2022-01-01 2022-06-30 0000903129 us-gaap:CostOfSalesMember us-gaap:CommodityContractMember 2022-04-01 2022-06-30 0000903129 country:FI 2023-04-01 2023-06-30 0000903129 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0000903129 thrm:EmployeeSeparationCostsMember thrm:OtherRestructuringActivitiesMember 2023-01-01 2023-06-30 0000903129 srt:MaximumMember thrm:SecondAmendedAndRestatedCreditAgreementMember thrm:TermSofrRateLoansMember 2023-01-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:SeatHeatersMember 2023-04-01 2023-06-30 0000903129 thrm:OtherLoansMember 2022-12-31 0000903129 us-gaap:InterestRateContractMember us-gaap:NondesignatedMember 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember thrm:AutomotiveSegmentMember 2022-12-31 0000903129 thrm:OtherLoansMember 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2022-01-01 2022-06-30 0000903129 us-gaap:OperatingSegmentsMember 2023-06-30 0000903129 country:RO 2023-04-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:LumbarAndMassageComfortSolutionsMember 2023-04-01 2023-06-30 0000903129 thrm:AccumulatedCommodityHedgeDerivativesAdjustmentMember 2021-12-31 0000903129 us-gaap:CorporateMember 2023-04-01 2023-06-30 0000903129 us-gaap:TradeNamesMember 2023-06-30 0000903129 us-gaap:CommodityContractMember 2023-01-01 2023-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000903129 thrm:SecondAmendedAndRestatedCreditAgreementMember 2023-06-30 0000903129 thrm:AlfmeierMember 2022-04-01 2022-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2022-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ElectronicsMember 2022-04-01 2022-06-30 0000903129 us-gaap:AccumulatedTranslationAdjustmentMember 2022-01-01 2022-06-30 0000903129 country:CZ 2023-01-01 2023-06-30 0000903129 thrm:BatteryPerformanceSolutionsBPSMember thrm:AutomotiveSegmentsMember 2023-01-01 2023-06-30 0000903129 thrm:AutomotiveSegmentsMember thrm:ClimateControlSeatMember 2023-04-01 2023-06-30 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission File Number: 0-21810

GENTHERM INCORPORATED

(Exact name of registrant as specified in its charter)

Michigan |  | 95-4318554
(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
21680 Haggerty Road, Northville, MI |  | 48167
(Address of principal executive offices) |  | (Zip Code)

Registrant’s telephone number, including area code: (248) 504-0500

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, no par value | THRM | Nasdaq

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer | ☒ |  | Accelerated filer | ☐
Non-accelerated filer | ☐ |  | Smaller reporting company | ☐
Emerging growth company | ☐ |  |  |

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

At July 26, 2023, there were 32,990,546 issued and outstanding shares of Common Stock of the registrant.

GENTHERM INCORPORATED

TABLE OF CONTENTS

Part I. Financial Information |  | 3
| Item 1. |  | Financial Statements (Unaudited) |  | 3
|  |  | Consolidated Condensed Balance Sheets |  | 3
|  |  | Consolidated Condensed Statements of (Loss) Income |  | 4
|  |  | Consolidated Condensed Statements of Comprehensive (Loss) Income |  | 5
|  |  | Consolidated Condensed Statements of Cash Flows |  | 6
|  |  | Consolidated Condensed Statements of Changes in Shareholders’ Equity |  | 7
|  |  | Notes to Unaudited Consolidated Condensed Financial Statements |  | 8
| Item 2. |  | Management’s Discussion and Analysis of Financial Condition and Results of Operations |  | 26
| Item 3. |  | Quantitative and Qualitative Disclosures About Market Risk |  | 39
| Item 4. |  | Controls and Procedures |  | 41
Part II. Other Information |  | 42
| Item 1. |  | Legal Proceedings |  | 42
| Item 1A. |  | Risk Factors |  | 42
| Item 2. |  | Unregistered Sales of Equity Securities and Use of Proceeds |  | 42
| Item 5. |  | Other Information |  | 42
| Item 6. |  | Exhibits |  | 43
Signatures |  | 44

2

PART I. FINANCIA L INFORMATION

ITEM 1. FINANC IAL STATEMENTS

GENTHERM INCORPORATED

CONSOLIDATED CONDEN SED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

|  | June 30, 2023 |  |  | December 31, 2022 |
ASSETS |  |  |  |  |  |
Current Assets: |  |  |  |  |  |
Cash and cash equivalents |  | $ | 168,671 |  |  | $ | 153,891 |
Accounts receivable, net |  |  | 258,157 |  |  |  | 247,131 |
Inventory: |  |  |  |  |  |
Raw materials |  |  | 129,972 |  |  |  | 136,217 |
Work in process |  |  | 15,673 |  |  |  | 17,695 |
Finished goods |  |  | 62,295 |  |  |  | 64,336 |
Inventory, net |  |  | 207,940 |  |  |  | 218,248 |
Other current assets |  |  | 74,781 |  |  |  | 64,597 |
Total current assets |  |  | 709,549 |  |  |  | 683,867 |
Property and equipment, net |  |  | 239,920 |  |  |  | 244,480 |
Goodwill |  |  | 100,885 |  |  |  | 119,774 |
Other intangible assets, net |  |  | 69,096 |  |  |  | 73,933 |
Operating lease right-of-use assets |  |  | 29,925 |  |  |  | 29,945 |
Deferred income tax assets |  |  | 74,537 |  |  |  | 69,840 |
Other non-current assets |  |  | 20,135 |  |  |  | 17,461 |
Total assets |  | $ | 1,244,047 |  |  | $ | 1,239,300 |
LIABILITIES AND SHAREHOLDERS’ EQUITY |  |  |  |  |  |
Current Liabilities: |  |  |  |  |  |
Accounts payable |  | $ | 207,655 |  |  | $ | 182,225 |
Current lease liabilities |  |  | 8,005 |  |  |  | 7,143 |
Current maturities of long-term debt |  |  | 684 |  |  |  | 2,443 |
Other current liabilities |  |  | 91,278 |  |  |  | 93,814 |
Total current liabilities |  |  | 307,622 |  |  |  | 285,625 |
Long-term debt, less current maturities |  |  | 217,441 |  |  |  | 232,653 |
Non-current lease liabilities |  |  | 18,095 |  |  |  | 20,538 |
Pension benefit obligation |  |  | 3,229 |  |  |  | 3,638 |
Other non-current liabilities |  |  | 27,100 |  |  |  | 24,573 |
Total liabilities |  | $ | 573,487 |  |  | $ | 567,027 |
Shareholders’ equity: |  |  |  |  |  |
Common Stock: |  |  |  |  |  |
No par value; 55,000,000 shares authorized 32,987,809 and 33,202,082 issued and outstanding at June 30, 2023 and December 31, 2022, respectively |  |  | 105,525 |  |  |  | 122,658 |
Paid-in capital |  |  | 5,379 |  |  |  | 5,447 |
Accumulated other comprehensive loss |  |  | (37,413 | ) |  |  | (46,489 | )
Accumulated earnings |  |  | 597,069 |  |  |  | 590,657 |
Total shareholders’ equity |  |  | 670,560 |  |  |  | 672,273 |
Total liabilities and shareholders’ equity |  | $ | 1,244,047 |  |  | $ | 1,239,300 |

3

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF (LOSS) INCOME

(In thousands, except per share data)

(Unaudited)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Product revenues |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 735,948 |  |  | $ | 528,372 |
Cost of sales |  |  | 284,335 |  |  |  | 201,338 |  |  |  | 566,830 |  |  |  | 404,882 |
Gross margin |  |  | 87,988 |  |  |  | 59,377 |  |  |  | 169,118 |  |  |  | 123,490 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |
Net research and development expenses |  |  | 24,696 |  |  |  | 19,325 |  |  |  | 49,841 |  |  |  | 39,759 |
Selling, general and administrative expenses |  |  | 38,418 |  |  |  | 31,943 |  |  |  | 75,460 |  |  |  | 61,251 |
Impairment of goodwill |  |  | 19,509 |  |  |  | — |  |  |  | 19,509 |  |  |  | — |
Restructuring expenses |  |  | 1,044 |  |  |  | 374 |  |  |  | 2,313 |  |  |  | 555 |
Total operating expenses |  |  | 83,667 |  |  |  | 51,642 |  |  |  | 147,123 |  |  |  | 101,565 |
Operating income |  |  | 4,321 |  |  |  | 7,735 |  |  |  | 21,995 |  |  |  | 21,925 |
Interest expense, net |  |  | (1,932 | ) |  |  | (1,430 | ) |  |  | (6,076 | ) |  |  | (1,999 | )
Foreign currency gain (loss) |  |  | 346 |  |  |  | 4,552 |  |  |  | (1,723 | ) |  |  | 6,769 |
Other income |  |  | 556 |  |  |  | 134 |  |  |  | 786 |  |  |  | 338 |
Earnings before income tax |  |  | 3,291 |  |  |  | 10,991 |  |  |  | 14,982 |  |  |  | 27,033 |
Income tax expense |  |  | 4,842 |  |  |  | 3,919 |  |  |  | 8,570 |  |  |  | 8,214 |
Net (loss) income |  | $ | (1,551 | ) |  | $ | 7,072 |  |  | $ | 6,412 |  |  | $ | 18,819 |
Basic (loss) earnings per share |  | $ | (0.05 | ) |  | $ | 0.21 |  |  | $ | 0.19 |  |  | $ | 0.57 |
Diluted (loss) earnings per share |  | $ | (0.05 | ) |  | $ | 0.21 |  |  | $ | 0.19 |  |  | $ | 0.56 |
Weighted average number of shares – basic |  |  | 33,019 |  |  |  | 33,119 |  |  |  | 33,100 |  |  |  | 33,077 |
Weighted average number of shares – diluted |  |  | 33,019 |  |  |  | 33,426 |  |  |  | 33,328 |  |  |  | 33,422 |

See accompanying notes to the consolidated condensed financial statements.

4

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME

(In thousands)

(Unaudited)

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Net (loss) income |  | $ | (1,551 | ) |  | $ | 7,072 |  |  | $ | 6,412 |  |  | $ | 18,819 |
Other comprehensive (loss) income: |  |  |  |  |  |  |  |  |  |  |  |
Pension benefit obligations |  |  | 4 |  |  |  | 27 |  |  |  | 8 |  |  |  | 56 |
Foreign currency translation adjustments |  |  | (3,588 | ) |  |  | (22,700 | ) |  |  | 4,667 |  |  |  | (31,994 | )
Unrealized gain (loss) on foreign currency derivative securities, net of tax |  |  | 2,272 |  |  |  | (247 | ) |  |  | 4,401 |  |  |  | 217 |
Unrealized loss on commodity derivative securities, net of tax |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (5 | )
Other comprehensive (loss) income, net of tax |  |  | (1,312 | ) |  |  | (22,920 | ) |  |  | 9,076 |  |  |  | (31,726 | )
Comprehensive (loss) income |  | $ | (2,863 | ) |  | $ | (15,848 | ) |  | $ | 15,488 |  |  | $ | (12,907 | )

See accompanying notes to the consolidated condensed financial statements.

5

GENTHERM INCORPORATED

CONSOLIDATED CONDENSED S TATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
Operating Activities: |  |  |  |  |  |
Net income |  | $ | 6,412 |  |  | $ | 18,819 |
Adjustments to reconcile net income to net cash provided by (used in) operating activities: |  |  |  |  |  |
Depreciation and amortization |  |  | 26,077 |  |  |  | 18,635 |
Deferred income taxes |  |  | (2,812 | ) |  |  | (997 | )
Stock based compensation |  |  | 5,053 |  |  |  | 5,263 |
Loss on disposition of property and equipment |  |  | 828 |  |  |  | 518 |
Provisions for inventory |  |  | 1,930 |  |  |  | 1,807 |
Impairment of goodwill |  |  | 19,509 |  |  |  | — |
Other |  |  | (259 | ) |  |  | 708 |
Changes in assets and liabilities: |  |  |  |  |  |
Accounts receivable, net |  |  | (11,624 | ) |  |  | (31,762 | )
Inventory |  |  | 9,417 |  |  |  | (35,444 | )
Other assets |  |  | (12,241 | ) |  |  | (10,443 | )
Accounts payable |  |  | 24,518 |  |  |  | 27,768 |
Other liabilities |  |  | (8,196 | ) |  |  | 1,442 |
Net cash provided by (used in) operating activities |  |  | 58,612 |  |  |  | (3,686 | )
Investing Activities: |  |  |  |  |  |
Purchases of property and equipment |  |  | (13,667 | ) |  |  | (15,448 | )
Proceeds from the sale of property and equipment |  |  | 40 |  |  |  | 81 |
Proceeds from deferred purchase price of factored receivables |  |  | 7,351 |  |  |  | — |
Cost of technology investments |  |  | (500 | ) |  |  | (350 | )
Net cash used in investing activities |  |  | (6,776 | ) |  |  | (15,717 | )
Financing Activities: |  |  |  |  |  |
Repayments of debt |  |  | (16,982 | ) |  |  | (1,250 | )
Proceeds from the exercise of Common Stock options |  |  | 263 |  |  |  | 569 |
Taxes withheld and paid on employees' share-based payment awards |  |  | (2,644 | ) |  |  | (4,464 | )
Cash paid for the repurchase of Common Stock |  |  | (19,993 | ) |  |  | — |
Net cash used in financing activities |  |  | (39,356 | ) |  |  | (5,145 | )
Foreign currency effect |  |  | 2,300 |  |  |  | (8,800 | )
Net increase (decrease) in cash and cash equivalents |  |  | 14,780 |  |  |  | (33,348 | )
Cash and cash equivalents at beginning of period |  |  | 153,891 |  |  |  | 190,606 |
Cash and cash equivalents at end of period |  | $ | 168,671 |  |  | $ | 157,258 |
Supplemental disclosure of cash flow information: |  |  |  |  |  |
Cash paid for taxes |  | $ | 11,619 |  |  | $ | 8,642 |
Cash paid for interest |  |  | 6,640 |  |  |  | 909 |
Non-Cash Investing Activities: |  |  |  |  |  |
Period-end balance of accounts payable for property and equipment |  | $ | 4,085 |  |  | $ | 1,747 |
Deferred purchase price of receivables factored in the period |  |  | 6,522 |  |  |  | — |

See accompanying notes to the consolidated condensed financial statements.

6

GENTHERM INCORPORATED

CONSOLIDA TED CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(In thousands)

(Unaudited)

|  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | Other |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Earnings |  |  | Total |
Balance at December 31, 2022 |  |  | 33,202 |  |  | $ | 122,658 |  |  | $ | 5,447 |  |  | $ | (46,489 | ) |  | $ | 590,657 |  |  | $ | 672,273 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,963 |  |  |  | 7,963 |
Other comprehensive income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 10,388 |  |  |  | — |  |  |  | 10,388 |
Stock compensation, net |  |  | 94 |  |  |  | (241 | ) |  |  | (68 | ) |  |  | — |  |  |  | — |  |  |  | (309 | )
Stock repurchase |  |  | (169 | ) |  |  | (9,997 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9,997 | )
Balance at March 31, 2023 |  |  | 33,127 |  |  | $ | 112,420 |  |  | $ | 5,379 |  |  | $ | (36,101 | ) |  | $ | 598,620 |  |  | $ | 680,318 |
Net loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,551 | ) |  |  | (1,551 | )
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (1,312 | ) |  |  | — |  |  |  | (1,312 | )
Stock compensation, net |  |  | 28 |  |  |  | 3,101 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,101 |
Stock repurchase |  |  | (167 | ) |  |  | (9,996 | ) |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (9,996 | )
Balance at June 30, 2023 |  |  | 32,988 |  |  | $ | 105,525 |  |  | $ | 5,379 |  |  | $ | (37,413 | ) |  | $ | 597,069 |  |  | $ | 670,560 |
|  |  |  |  |  |  |  |  |  |  | Accumulated |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | Other |  |  |  |  |  |  |
|  | Common Stock |  |  | Paid-in |  |  | Comprehensive |  |  | Accumulated |  |  |  |
|  | Shares |  |  | Amount |  |  | Capital |  |  | Loss |  |  | Earnings |  |  | Total |
Balance at December 31, 2021 |  |  | 33,008 |  |  | $ | 118,646 |  |  | $ | 5,866 |  |  | $ | (36,922 | ) |  | $ | 566,216 |  |  | $ | 653,806 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 11,747 |  |  |  | 11,747 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (8,806 | ) |  |  |  |  |  | (8,806 | )
Stock compensation, net |  |  | 119 |  |  |  | (814 | ) |  |  | (146 | ) |  |  | — |  |  |  |  |  |  | (960 | )
Balance at March 31, 2022 |  |  | 33,127 |  |  | $ | 117,832 |  |  | $ | 5,720 |  |  | $ | (45,728 | ) |  | $ | 577,963 |  |  | $ | 655,787 |
Net income |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 7,072 |  |  |  | 7,072 |
Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (22,920 | ) |  |  | — |  |  |  | (22,920 | )
Stock compensation, net |  |  | 6 |  |  |  | 3,256 |  |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 3,256 |
Balance at June 30, 2022 |  |  | 33,133 |  |  | $ | 121,088 |  |  | $ | 5,720 |  |  | $ | (68,648 | ) |  | $ | 585,035 |  |  | $ | 643,195 |

See accompanying notes to the consolidated condensed financial statements.

7

Note 1 – Overview

Gentherm Incorporated, a Michigan corporation, and its consolidated subsidiaries (“Gentherm”, “we”, “us”, “our” or the “Company”) is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the US, China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

Basis of Presentation and Significant Accounting Policies

The unaudited consolidated condensed financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to those rules and regulations. The information furnished in the consolidated condensed financial statements include all adjustments (consisting of only normal, recurring adjustments) considered necessary to present fairly the results of operations, financial position and cash flows of the Company. These financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022. The operating results for interim periods are not necessarily indicative of results that may be expected for any other interim period or for the full year.

In preparing these financial statements, management was required to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. These estimates and assumptions are based on our historical experience, the terms of existing contracts, our evaluation of trends in the industry, information provided by our customers and suppliers and information available from other outside sources, as appropriate. These estimates and assumptions are subject to an inherent degree of uncertainty. We are not presently aware of any events or circumstances that would require us to update such estimates and assumptions or revise the carrying value of our assets or liabilities. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Principles of Consolidation

The consolidated condensed financial statements include the accounts of the Company, its wholly owned subsidiaries and those entities in which it has a controlling financial interest. The Company evaluates its relationship with other entities for consolidation and to identify whether such entities are variable interest entities (“VIE”) and to assess whether the Company is the primary beneficiary of such entities. Investments in entities in which Gentherm does not have control but does have the ability to exercise significant influence over operating and financial policies are accounted for under the equity method. When Gentherm does not have the ability to exercise significant influence (generally when ownership interest is less than 20%), investments in entities are measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer.

Variable Interest Entities

The Company maintains an ownership interest in a VIE, Carrar Ltd. (“Carrar”). Carrar is a technology developer of advanced thermal management systems for the electric mobility market. The Company determined that Carrar is a VIE; however, the Company does not have a controlling financial interest or have the power to direct the activities that most significantly affect the economic performance of the investment. Therefore, the Company has concluded that it is not the primary beneficiary. Gentherm’s investment in Carrar is measured at cost, less impairments, adjusted for observable price changes in orderly transactions for identical or similar investments of the same issuer. The Carrar investment was $5,700 and $5,200 as of June 30, 2023 and December 31, 2022, respectively, and is recorded in Other non-current assets in the consolidated condensed balance sheets.

8

Revenue Recognition

The Company has no material contract assets or contract liabilities as of June 30, 2023.

The Company recognizes an asset for the incremental costs of obtaining a contract with a customer if the benefits of those costs are expected to be realized for a period greater than one year. Total capitalized costs to obtain a contract were $3,849 and $2,239 as of June 30, 2023 and December 31, 2022, respectively. These amounts are recorded in Other non-current assets in the consolidated condensed balance sheets and are being amortized into Product revenues in the consolidated condensed statements of (loss) income over the expected production life of the applicable program.

Note 2 – Acquisitions

Alfmeier Präzision SE

On August 1, 2022, the Company acquired 100% of the equity interests of Alfmeier Präzision SE (“Alfmeier”), a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned with global consumer demand for expanded offerings in vehicle passenger comfort.

The total consideration transferred was $170,700. The results of Alfmeier's operations are reported within the Automotive segment from the acquisition date.

The acquisition was accounted for as a business combination. As of June 30, 2023, the purchase consideration and fair values of assets and liabilities assumed are final. The following table summarizes the purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments:

|  | Initial Allocation as of August 1, 2022 |  |  | Measurement Period Adjustments |  |  | Final Allocation as of June 30, 2023 |
Purchase price, cash consideration, net of cash acquired |  | $ | 164,887 |  |  | $ | 5,813 |  |  | $ | 170,700 |
|  |  |  |  |  |  |  |  | — |
Accounts receivable |  |  | 24,988 |  |  |  | (121 | ) |  |  | 24,867 |
Inventory |  |  | 36,026 |  |  |  | 417 |  |  |  | 36,443 |
Prepaid expenses and other assets |  |  | 20,920 |  |  |  | (74 | ) |  |  | 20,846 |
Operating lease right-of-use assets |  |  | 4,608 |  |  |  | — |  |  |  | 4,608 |
Property and equipment |  |  | 89,942 |  |  |  | 1,242 |  |  |  | 91,184 |
Other intangible assets |  |  | 22,668 |  |  |  | 8,791 |  |  |  | 31,459 |
Goodwill |  |  | 43,678 |  |  |  | (9,707 | ) |  |  | 33,971 |
Assumed liabilities |  |  | (55,994 | ) |  |  | 975 |  |  |  | (55,019 | )
Deferred tax liabilities |  |  | (21,949 | ) |  |  | 4,290 |  |  |  | (17,659 | )
Net assets acquired |  | $ | 164,887 |  |  | $ | 5,813 |  |  | $ | 170,700 |

The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired:

|  | Final Fair Value |  |  | Weighted Average Life (in years) |
Definite-lived: |  |  |  |  |  |
Customer related |  | $ | 19,812 |  |  |  | 14 |
Technology |  |  | 11,647 |  |  |  | 9 |
Total |  | $ | 31,459 |  |  |  |

Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable.

The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from combining operations to offer more compelling and high-value solutions across complementary customer relationships as well as expected future synergies. The goodwill is not expected to be deductible for tax purposes.

9

The following unaudited pro forma information represents our product revenues as if the acquisition of Alfmeier had occurred as of January 1, 2022:

|  | Three Months Ended June 30, 2022 |  |  | Six Months Ended June 30, 2022 |
Product revenues |  | $ | 318,341 |  |  | $ | 652,097 |
Net income |  |  | 3,731 |  |  |  | 12,297 |

Jiangmen Dacheng Medical Equipment Co. Ltd

On July 13, 2022, the Company acquired 100% of the equity interests of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng is a privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site.

The total consideration transferred was $35,048. The purchase agreement also included potential cash payments contingent upon the achievement of certain performance metrics and continued employment of the former majority shareholder through a series of defined dates. The achievement of these performance metrics resulted in cash payments of $500. These cash payments were accounted for as compensation expense and recorded as a component of Selling, general and administrative expenses ratably over the service period.

The acquisition was accounted for as a business combination. As of June 30, 2023, the purchase consideration and fair values of assets and liabilities assumed are final. The following table summarizes the purchase consideration and estimated fair values of assets acquired and liabilities assumed as of the acquisition date and subsequent measurement period adjustments:

|  | Initial Allocation as of July 13, 2022 |  |  | Measurement Period Adjustments |  |  | Final Allocation as of June 30, 2023 |
Purchase price, cash consideration, net of cash acquired |  | $ | 35,048 |  |  | $ | — |  |  | $ | 35,048 |
|  |  |  |  |  |  |  |  | — |
Accounts receivable |  |  | 746 |  |  |  | (124 | ) |  |  | 622 |
Inventory |  |  | 1,942 |  |  |  | (177 | ) |  |  | 1,765 |
Prepaid expenses and other assets |  |  | 152 |  |  |  | 22 |  |  |  | 174 |
Operating lease right-of-use assets |  |  | 841 |  |  |  | — |  |  |  | 841 |
Property and equipment |  |  | 684 |  |  |  | — |  |  |  | 684 |
Other intangible assets |  |  | 19,094 |  |  |  | 965 |  |  |  | 20,059 |
Goodwill |  |  | 22,995 |  |  |  | (3,464 | ) |  |  | 19,531 |
Assumed liabilities |  |  | (2,799 | ) |  |  | (515 | ) |  |  | (3,314 | )
Deferred tax liabilities |  |  | (8,607 | ) |  |  | 3,293 |  |  |  | (5,314 | )
Net assets acquired |  | $ | 35,048 |  |  | $ | — |  |  | $ | 35,048 |

The following table summarizes the final allocation of the purchase consideration to the other intangible assets acquired:

|  | Final Fair Value |  |  | Weighted Average Life (in years) |
Definite-lived: |  |  |  |  |  |
Customer related |  | $ | 12,837 |  |  |  | 12 |
Technology |  |  | 4,749 |  |  |  | 12 |
Indefinite-lived: |  |  |  |  |  |
Tradenames |  |  | 2,473 |  |  |  | — |
Total |  | $ | 20,059 |  |  |  |

Assets acquired and liabilities assumed were recorded at estimated fair values based on third-party valuations, management’s estimates, available information, and supportable assumptions that management considered reasonable. The fair value of the intangible assets was based on third-party valuations and management’s estimates, generally utilizing income and market approaches. Goodwill recognized in this transaction is primarily attributable to the Company’s expected future economic benefits from the enhanced access to high-growth markets including private label opportunities through Dacheng’s innovative patient temperature management devices. The goodwill is not expected to be deductible for tax purposes.

10

The pro forma effects of this acquisition would not materially impact the Company’s reported results for any period presented, and as a result no pro forma financial statements are presented.

Note 3 – Restructuring and Impairments

The Company continuously monitors market developments, industry trends and changing customer needs and in response, may undertake restructuring actions, as necessary, to execute management’s strategy, streamline operations and optimize the Company’s cost structure. Restructuring actions may include the realignment of existing manufacturing footprint, facility closures, or similar actions, either in the normal course of business or pursuant to significant restructuring programs.

These actions may result in employees receiving voluntary or involuntary employee termination benefits, which are mainly statutory requirements or other contractual agreements. Voluntary termination benefits are accrued when an employee accepts the related offer. Involuntary termination benefits are accrued upon the commitment to a termination plan and when the benefit arrangement is communicated to affected employees, or when liabilities are determined to be probable and estimable, depending on the existence of a substantive plan for severance or termination.

Manufacturing Footprint Rationalization

During 2019, the Company committed to a restructuring plan (“Plan”) to improve the Company’s manufacturing productivity and rationalize its footprint. Under this Plan, the Company relocated and consolidated certain automotive electronics manufacturing plants in North America and China.

During the three and six months ended June 30, 2023, the Company did no t recognize any restructuring expense. During the three and six months ended June 30, 2022, the Company recognized restructuring expense of $0 and $50, respectively, for employee separation costs and $97 and $198, respectively, for other costs.

The Company has recorded approximately $10,359 of restructuring expenses since the inception of this program and as of June 30, 2023, $588 remains accrued.

Other Restructuring Activities

The Company has undertaken several discrete restructuring actions. During the three and six months ended June 30, 2023, the Company recognized $337 and $1,543 for employee separation costs, respectively, and $707 and $770, respectively, of other costs. During the three and six months ended June 30, 2022, the Company recognized $277 and $307, respectively, for other costs. These restructuring expenses were primarily associated with restructuring actions focused on the reduction of global overhead costs.

Restructuring Expenses By Reporting Segment

The following table summarizes restructuring expense for the three and six months ended June 30, 2023 and 2022 by reporting segment:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Automotive |  | $ | 296 |  |  | $ | 374 |  |  | $ | 1,370 |  |  | $ | 555 |
Medical |  |  | — |  |  |  | — |  |  |  | — |  |  |  | — |
Corporate |  |  | 748 |  |  |  | — |  |  |  | 943 |  |  |  | — |
Total |  | $ | 1,044 |  |  | $ | 374 |  |  | $ | 2,313 |  |  | $ | 555 |

11

Restructuring Liability

Restructuring liabilities are classified as other current liabilities in the consolidated condensed balance sheets. The following table summarizes restructuring liability for the six months ended June 30, 2023:

|  | Employee Separation Costs |  |  | Other Related Costs |  |  | Total |
Balance at December 31, 2022 |  | $ | 588 |  |  | $ | — |  |  | $ | 588 |
Additions, charged to restructuring expenses |  |  | 1,206 |  |  |  | 63 |  |  |  | 1,269 |
Cash payments |  |  | — |  |  |  | (63 | ) |  |  | (63 | )
Currency translation |  |  | 16 |  |  |  | — |  |  |  | 16 |
Balance at March 31, 2023 |  | $ | 1,810 |  |  | $ | — |  |  | $ | 1,810 |
Additions, charged to restructuring expenses |  |  | 337 |  |  |  | 707 |  |  |  | 1,044 |
Cash payments |  |  | (565 | ) |  |  | (707 | ) |  |  | (1,272 | )
Currency translation |  |  | 6 |  |  |  | — |  |  |  | 6 |
Balance at June 30, 2023 |  | $ | 1,588 |  |  | $ | — |  |  | $ | 1,588 |

Impairments

Non-Automotive Electronics Business

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $9,378, $5,601 and $690 for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.

During the three and six months ended June 30, 2023, the Company recorded non-cash impairment charges of $644 and $2,063, respectively, for the write down of inventory within the Automotive segment. This charge was recorded in Cost of sales.

The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.

Medical Segment

During the three months ended June 30, 2023, the Company determined that there were impairment indicators for its Medical reporting unit and conducted an impairment analysis, following which the Company concluded that $19,509 of goodwill was impaired. Such non-cash impairment charge was recorded in Impairment of goodwill for the three and six months ended June 30, 2023. See Note 5 for additional information about the goodwill impairment analysis.

12

Note 4 – Details of Certain Balance Sheet Components

|  | June 30, 2023 |  |  | December 31, 2022 |
Other current assets: |  |  |  |  |  |
Billable tooling |  | $ | 17,393 |  |  | $ | 15,267 |
Income tax and other tax receivable |  |  | 13,197 |  |  |  | 15,041 |
Notes receivable |  |  | 13,176 |  |  |  | 12,127 |
Short-term derivative financial instruments |  |  | 12,825 |  |  |  | 6,564 |
Prepaid expenses |  |  | 9,631 |  |  |  | 6,239 |
Receivables due from factor |  |  | 5,177 |  |  |  | 5,490 |
Other |  |  | 3,382 |  |  |  | 3,869 |
Total other current assets |  | $ | 74,781 |  |  | $ | 64,597 |
Other current liabilities: |  |  |  |  |  |
Accrued employee liabilities |  | $ | 36,074 |  |  | $ | 32,031 |
Liabilities from discounts and rebates |  |  | 25,266 |  |  |  | 26,640 |
Income tax and other taxes payable |  |  | 14,828 |  |  |  | 14,459 |
Accrued warranty |  |  | 2,900 |  |  |  | 2,380 |
Restructuring |  |  | 1,588 |  |  |  | 588 |
Other |  |  | 10,622 |  |  |  | 17,716 |
Total other current liabilities |  | $ | 91,278 |  |  | $ | 93,814 |

Note 5 – Goodwill and Other Intangibles

Goodwill

Changes in the carrying amount of goodwill, by reportable segment, for the six months ended June 30, 2023 was as follows:

|  | Automotive |  |  | Medical |  |  | Total |
Balance as of December 31, 2022 |  | $ | 73,069 |  |  | $ | 46,705 |  |  | $ | 119,774 |
Impairment of goodwill |  |  | — |  |  |  | (19,509 | ) |  |  | (19,509 | )
Currency translation |  |  | 759 |  |  |  | (139 | ) |  |  | 620 |
Balance as of June 30, 2023 |  | $ | 73,828 |  |  | $ | 27,057 |  |  | $ | 100,885 |

Other Intangible Assets

Other intangible assets and accumulated amortization balances as of June 30, 2023 and December 31, 2022 were as follows:

|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |  |  | Gross Carrying Value |  |  | Accumulated Amortization |  |  | Net Carrying Value |
Definite-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Customer relationships |  | $ | 113,792 |  |  | $ | (70,591 | ) |  | $ | 43,201 |  |  | $ | 112,286 |  |  | $ | (65,748 | ) |  | $ | 46,538 |
Technology |  |  | 45,296 |  |  |  | (27,563 | ) |  |  | 17,733 |  |  |  | 44,745 |  |  |  | (25,709 | ) |  |  | 19,036 |
Product development costs |  |  | 19,134 |  |  |  | (18,968 | ) |  |  | 166 |  |  |  | 18,774 |  |  |  | (18,456 | ) |  |  | 318 |
Software development |  |  | 1,007 |  |  |  | — |  |  |  | 1,007 |  |  |  | 1,007 |  |  |  | — |  |  |  | 1,007 |
Indefinite-lived: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Tradenames |  |  | 6,989 |  |  |  | — |  |  |  | 6,989 |  |  |  | 7,034 |  |  |  | — |  |  |  | 7,034 |
Total |  | $ | 186,218 |  |  | $ | (117,122 | ) |  | $ | 69,096 |  |  | $ | 183,846 |  |  | $ | (109,913 | ) |  | $ | 73,933 |

As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10%. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit by $17,086, and accordingly an impairment expense was recorded for $19,509 that includes the associated deferred tax effect that was measured using the simultaneous equation method.

13

The Company utilized an income approach to estimate the fair value of the reporting unit and a market valuation approach to further support this analysis (level 3). The income approach was based on projected debt-free cash flow that was discounted to the present value using discount factors that considered the timing and risk of cash flows. Fair value was estimated using internally developed forecasts, as well as commercial and discount rate assumptions. The discount rate used was the value-weighted average of our estimated cost of equity and of debt (“cost of capital”) derived using both known and estimated customary market metrics. Our weighted average cost of capital includes a company specific risk premium to address the risks associated with achieving the projected revenue and profitability growth rates. Other significant assumptions included terminal value growth rates and terminal value margin rates. Our ability to realize the future cash flows used in our calculations is affected by factors such as the success of strategic initiatives, changes in economic conditions, changes in our operating performance and changes in our business strategies. To further support the fair value estimate determined by the income approach, the Company utilized a market valuation approach to estimate the fair value of the Medical reporting unit. The market approach considered historical and anticipated financial metrics of the Medical reporting unit and applied valuation multiples based on recent observed transactions involving companies similar enough to the Medical reporting unit from which to draw meaningful conclusions.

Note 6 – Debt

The following table summarizes the Company’s debt as of June 30, 2023 and December 31, 2022:

|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Interest Rate |  |  | Principal Balance |  |  | Interest Rate |  |  | Principal Balance |
Credit Agreement: |  |  |  |  |  |  |  |  |  |  |  |
Revolving Credit Facility (U.S. Dollar denominations) |  |  | 6.58 | % |  | $ | 217,000 |  |  |  | 5.80 | % |  | $ | 232,000 |
Other loans |  |  | 3.90 | % |  |  | 269 |  |  | 3.89% - 5.21% |  |  |  | 2,011 |
Finance leases |  | N/A |  |  |  | 856 |  |  | N/A |  |  |  | 1,085 |
Total debt |  |  |  |  |  | 218,125 |  |  |  |  |  |  | 235,096 |
Current maturities |  |  |  |  |  | (684 | ) |  |  |  |  |  | (2,443 | )
Long-term debt, less current maturities |  |  |  |  | $ | 217,441 |  |  |  |  |  | $ | 232,653 |

Credit Agreement

On June 10, 2022, the Company entered into a Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent (the “Agent”).

The Second Amended and Restated Credit Agreement provides for a $500,000 secured revolving credit facility (the “Revolving Credit Facility”), with a $50,000 sublimit for swing line loans and a $15,000 sublimit for the issuance of standby letters of credit. Any amount of the facility utilized for swing line loans or lett ers of credit outstanding will reduce the amount available under the Second Amended and Restated Credit Agreement. The Company had no outsta nding letters of credit issued as of June 30, 2023 and December 31, 2022.

Subject to specified conditions, Gentherm can increase the Revolving Credit Facility or incur secured term loans in an aggregate amount of up to $200,000. The Second Amended and Restated Credit Agreement matures on June 10, 2027.

The U.S. borrowers and guarantors participating in the Second Amended and Restated Credit Agreement also entered into a Second Amended and Restated Pledge and Security Agreement (the “Second Amended and Restated Security Agreement”). The Second Amended and Restated Security Agreement grants a security interest to the Agent in substantially all of the personal property of the Company and its U.S. subsidiaries designated as borrowers to secure their respective obligations under the Second Amended and Restated Security Agreement, including the stock and membership interests of specified subsidiaries (limited to 66% of the stock in the case of certain non-U.S. subsidiaries). In addition to the security obligations, all obligations under the Second Amended and Restated Credit Agreement (including all obligations of any U.S. or non-U.S. loan party) are unconditionally guaranteed by certain of Gentherm’s domestic subsidiaries, and the German subsidiary borrowers and certain other foreign subsidiaries guarantee all obligations of the non-U.S. loan parties under the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement restricts, among other things, the amount of dividend payments the Company can make to shareholders.

14

The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. The Second Amended and Restated Credit Agreement also contains customary events of default. As of June 30, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement. The Second Amended and Restated Credit Agreement additionally contains customary events of default. Upon the occurrence of an event of default, the amounts outstanding under the Revolving Credit Facility may be accelerated and may become immediately due and payable.

Under the Second Amended and Restated Credit Agreement, U.S. Dollar denominated loans bear interest at either a base rate (“Base Rate Loans”) or Term SOFR rate (“Term SOFR Rate Loans”), plus a margin (“Applicable Rate”). The rate for Base Rate Loans is equal to the highest of the Federal Funds Rate plus 0.50%, Bank of America’s prime rate, or the Term SOFR rate plus 1.00%. The rate for Term SOFR Rate Loans denominated in U.S. Dollars is equal to the forward-looking Secured Overnight Financing Rate (“SOFR”) term rate administered by the CME with a term of one month. All loans denominated in a currency other than the U.S. Dollar must be Term SOFR Rate Loans. Interest is payable at least quarterly. Additionally, a commitment fee of between 0.175% to 0.300%, which will vary based on the Consolidated Net Leverage Ratio, as defined in the Second Amended and Restated Credit Agreement, is payable on the average daily unused amounts under the Revolving Credit Facility.

The Applicable Rate varies based on the Consolidated Net Leverage Ratio reported by the Company. As long as the Company is not in default of the terms and conditions of the Second Amended and Restated Credit Agreement, the lowest and highest possible Applicable Rate is 1.125% and 2.125%, respectively, for Term SOFR Rate Loans and 0.125% and 1.125%, respectively, for Base Rate Loans.

Borrowing availability is subject to, among other things, the Company’s compliance with the minimum Consolidated Interest Coverage Ratio and the maximum Consolidated Net Leverage Ratio as of the end of any fiscal quarter. Based upon consolidated EBITDA for the trailing four fiscal quarters calculated for purposes of the Consolidated Net Leverag e Ratio, $282,732 r emained available as of June 30, 2023 for additional borrowings under the Second Amended and Restated Credit Agreement subject to specified conditions that Gentherm currently satisfies.

In connection with the Second Amended and Restated Credit Agreement, the Company incurred debt issuance costs of $1,417, which have been capitalized and will be amortized into Interest expense, net over the term of the credit facility.

The scheduled principal maturities of our debt as of June 30, 2023 were as follows:

|  | U.S. Revolving Note |  |  | Other Debt |  |  | Total |
2023 |  | $ | — |  |  | $ | 471 |  |  | $ | 471 |
2024 |  |  | — |  |  |  | 434 |  |  |  | 434 |
2025 |  |  | — |  |  |  | 151 |  |  |  | 151 |
2026 |  |  | — |  |  |  | 69 |  |  |  | 69 |
2027 |  |  | 217,000 |  |  |  | — |  |  |  | 217,000 |
2028 |  |  | — |  |  |  | — |  |  |  | — |
Total |  | $ | 217,000 |  |  | $ | 1,125 |  |  | $ | 218,125 |

Note 7 – Commitments and Contingencies

Legal and other contingencies

The Company may be subject to various legal actions and claims in the ordinary course of its business, including those arising out of breach of contracts, intellectual property rights, environmental matters, regulatory matters and employment-related matters. The Company establishes accruals for matters which it believes that losses are probable and can be reasonably estimated. Although it is not possible to predict with certainty the outcome of these matters, the Company is of the opinion that the ultimate resolution of these

15

matters will not have a material adverse effect on its results of operations or financial position. Product liability and warranty reserves are recorded separately from legal reserves.

Product Liability and Warranty Matters

In the event that the Company’s products fail to perform as expected or result in alleged bodily injury or property damage, our products may subject us to warranty claims and product liability. If any of our products are or are alleged to be defective, we may be required to participate in a recall or other corrective action involving such products. The Company maintains liability insurance coverage at levels based on commercial norms and historical claims experience. The Company can provide no assurances that it will not experience material claims or liabilities in the future or that it will not incur significant costs to defend such claims.

The Company accrues warranty obligations for products sold based on management estimates of future failure rates and current claim cost experience, with support from the sales, engineering, quality and legal functions. Using historical information available to the Company, including any claims filed by customers, the warranty accrual is adjusted quarterly to reflect management’s estimate of future claims.

The following is a reconciliation of the changes in accrued warranty costs:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
Balance at the beginning of the period |  | $ | 2,380 |  |  | $ | 1,916 |
Warranty claims paid |  |  | (1,673 | ) |  |  | (623 | )
Warranty expense for products shipped during the current period |  |  | 2,215 |  |  |  | 818 |
Adjustments to warranty estimates from prior periods |  |  | (32 | ) |  |  | (171 | )
Adjustments due to currency translation |  |  | 10 |  |  |  | (41 | )
Balance at the end of the period |  | $ | 2,900 |  |  | $ | 1,899 |

Other matters

Purchase commitments for materials, supplies, services and capital expenditures, as part of the normal course of business, are generally consistent from year to year. In addition, due to supply shortages of semiconductors, the Company has entered into agreements with various suppliers to reserve the right to purchase certain semiconductor chips over rolling periods of 12-24 months, with volume commitments determined based on our anticipated production requirements. As of June 30, 2023, the Company’s total commitments for these semiconductor chip agreements was $34,646. Such agreements provide the Company with priority access to semiconductor chips as they become available, however, these agreements do not guarantee that our suppliers will meet the timing and quantities requested by Gentherm. All other purchase commitments as of June 30, 2023 were immaterial.

16

Note 8 – (Loss) Earnings Per Share

Basic (loss) earnings per share are computed by dividing net (loss) income by the weighted average number of shares of Common Stock outstanding during the period. The Company’s diluted (loss) earnings per share give effect to all potential shares of Common Stock outstanding during a period that do not have an anti-dilutive impact to the calculation. In computing the diluted (loss) earnings per share, the treasury stock method is used in determining the number of shares assumed to be issued from the exercise of Common Stock equivalents.

The following table illustrates earnings per share and the weighted average shares outstanding used in calculating basic and diluted earnings per share:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Net (loss) income |  | $ | (1,551 | ) |  | $ | 7,072 |  |  | $ | 6,412 |  |  | $ | 18,819 |
Basic weighted average shares of Common Stock outstanding |  |  | 33,018,939 |  |  |  | 33,119,085 |  |  |  | 33,099,817 |  |  |  | 33,077,029 |
Dilutive effect of stock options, restricted stock awards and restricted stock units |  |  | — |  |  |  | 307,038 |  |  |  | 228,160 |  |  |  | 344,958 |
Diluted weighted average shares of Common Stock outstanding |  |  | 33,018,939 |  |  |  | 33,426,123 |  |  |  | 33,327,977 |  |  |  | 33,421,987 |
Basic (loss) earnings per share |  | $ | (0.05 | ) |  | $ | 0.21 |  |  | $ | 0.19 |  |  | $ | 0.57 |
Diluted (loss) earnings per share |  | $ | (0.05 | ) |  | $ | 0.21 |  |  | $ | 0.19 |  |  | $ | 0.56 |

The following table represents Common Stock issuable upon the exercise of certain restricted stock awards and restricted stock units that have been excluded from the diluted earnings calculation because the effect of their inclusion would be anti-dilutive.

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Anti-dilutive securities share impact |  |  | 198,371 |  |  |  | — |  |  |  | — |  |  |  | — |

Note 9 – Financial Instruments

Derivative Financial Instruments

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to its debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts which can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of (loss) income on the same line as the

17

gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of designated foreign currency and copper commodity hedging instruments, if any, to Cost of sales in the consolidated condensed statements of (loss) income. Cash flows associated with derivatives are reported in Net cash provided by (used in) operating activities in the consolidated condensed statements of cash flows.

The Company uses an income approach to value derivative instruments, analyzing quoted market prices to calculate the forward values and then discounting such forward values to the present value using benchmark rates at commonly quoted intervals for the instrument’s full term.

The Company is party to a floating-to-fixed interest rate swap agreement with a notional amount of $100,000 and a maturity date of July 2025. This interest rate swap is an undesignated hedge of the Company’s exposure to interest payment fluctuations on a portion of the Revolving Credit Facility borrowings that were drawn for the acquisitions of Alfmeier and Dacheng. The periodic changes in fair value is recognized in Interest expense, net.

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of June 30, 2023 is as follows:

|  |  |  |  |  |  | Asset Derivatives |  |  | Liability Derivatives |  |  |  |
|  | Fair Value Hierarchy |  | Notional Amount |  |  | Balance Sheet Location |  | Fair Value |  |  | Balance Sheet Location |  | Fair Value |  |  | Net Asset/ (Liabilities) |
Derivatives Designated as Cash Flow Hedges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency derivatives |  | Level 2 |  | $ | 54,861 |  |  | Other current assets |  | $ | 9,380 |  |  | Other current liabilities |  | $ | — |  |  | $ | 9,380 |
Derivatives Not Designated as Hedging Instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate contracts |  | Level 2 |  | $ | 100,000 |  |  | Other current assets |  | $ | 3,445 |  |  | Other current liabilities |  | $ | — |  |  | $ | 3,445 |

Information related to the recurring fair value measurement of derivative instruments in our consolidated condensed balance sheet as of December 31, 2022 is as follows:

|  |  |  |  |  |  | Asset Derivatives |  |  | Liability Derivatives |  |  |  |
|  | Fair Value Hierarchy |  | Notional Amount |  |  | Balance Sheet Location |  | Fair Value |  |  | Balance Sheet Location |  | Fair Value |  |  | Net Asset/ (Liabilities) |
Derivatives Designated as Cash Flow Hedges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency derivatives |  | Level 2 |  | $ | 40,063 |  |  | Other current assets |  | $ | 3,791 |  |  | Other current liabilities |  | $ | — |  |  | $ | 3,791 |
Derivatives Not Designated as Hedging Instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate contracts |  | Level 2 |  | $ | 100,000 |  |  | Other current assets |  | $ | 2,772 |  |  | Other current liabilities |  | $ | — |  |  | $ | 2,772 |

18

Information relating to the effect of derivative instruments on our consolidated condensed statements of (loss) income and the consolidated condensed statements of comprehensive (loss) income is as follows:

|  |  |  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | Location (Income/(Loss)) |  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Derivatives Designated as Cash Flow Hedges |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency derivatives |  | Cost of sales – income |  | $ | 1,984 |  |  | $ | 333 |  |  | $ | 3,043 |  |  | $ | 486 |
|  | Other comprehensive income (loss) |  |  | 2,905 |  |  |  | (316 | ) |  |  | 5,588 |  |  |  | 294 |
Total foreign currency derivatives |  |  |  | $ | 4,889 |  |  | $ | 17 |  |  | $ | 8,631 |  |  | $ | 780 |
Commodity derivatives |  | Cost of sales – income |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 19 |
|  | Other comprehensive loss |  |  | — |  |  |  | — |  |  |  | — |  |  |  | (6 | )
Total commodity derivatives |  |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 13 |
Derivatives Not Designated as Hedging Instruments |  |  |  |  |  |  |  |  |  |  |  |  |  |
Foreign currency derivatives |  | Foreign currency gain |  | $ | — |  |  | $ | 482 |  |  | $ | — |  |  | $ | 482 |
Total foreign currency derivatives |  |  |  | $ | — |  |  | $ | 482 |  |  | $ | — |  |  | $ | 482 |
Interest rate contracts |  | Interest expense, net |  | $ | 1,371 |  |  | $ | (693 | ) |  | $ | 672 |  |  | $ | (693 | )
Total interest rate derivatives |  |  |  | $ | 1,371 |  |  | $ | (693 | ) |  | $ | 672 |  |  | $ | (693 | )

The Company did no t incur any hedge ineffectiveness during the three and six months ended June 30, 2023 and 2022.

Accounts Receivable Factoring

The Company sells certain customer trade receivables on a non-recourse basis under factoring arrangements with designated financial institutions. The sale of receivables under these agreements is considered an off-balance sheet arrangement to the Company and is accounted for as a true sale and excluded from accounts receivable in the consolidated condensed balance sheets. These factoring arrangements include a deferred purchase price component in which a portion of the purchase price for the receivable is paid by the financial institution in cash upon sale and the remaining portion is recorded as a deferred purchase price receivable and paid at a later date. Deferred purchase price receivables are recorded in Other current assets within the consolidated condensed balance sheets. Cash proceeds received upon the sale of the receivables are included in Net cash provided by (used in) operating activities and the cash proceeds received on the deferred purchase price receivables are included in Net cash used in investing activities. All factoring arrangements incorporate customary representations, including representations as to validity of amounts due, completeness of performance obligations and absence of commercial disputes.

Receivables factored and availability under receivables factoring agreements balances as of June 30, 2023 and December 31, 2022 were as follows:

|  | June 30, 2023 |  |  | December 31, 2022 |
Receivables factored and outstanding |  | $ | 21,623 |  |  | $ | 19,108 |
Amount available under the credit limit |  |  | 2,471 |  |  |  | 5,034 |
Collective factoring limit |  | $ | 24,094 |  |  | $ | 24,142 |

Trade receivables sold and factoring fees incurred during the three and six months ended June 30, 2023 and 2022 were as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Trade receivables sold |  | $ | 38,261 |  |  | $ | — |  |  | $ | 76,801 |  |  | $ | — |
Factoring fees incurred |  |  | 207 |  |  |  | — |  |  |  | 368 |  |  |  | — |

19

Note 10 – Fair Value Measurements

Fair value is defined as the exchange price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Fair value measurements are based on one or more of the following three valuation techniques:

Market: This approach uses prices and other relevant information generated by market transactions involving identical or comparable assets or liabilities.

Income: This approach uses valuation techniques to convert future amounts to a single present value amount based on current market expectations.

Cost: This approach is based on the amount that would be required to replace the service capacity of an asset (replacement cost).

The Company uses the following fair value hierarchy to measure fair value into three broad levels, which are described below:

Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs, other than quoted market prices included in Level 1, that are observable either directly or indirectly for the asset or liability.

Level 3: Unobservable inputs that are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Items Measured at Fair Value on a Recurring Basis

Except for derivative instruments (see Note 9) and pension plan assets, the Company had no material financial assets and liabilities that were carried at fair value at June 30, 2023 and December 31, 2022. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and also considers counterparty credit risk in its assessment of fair value.

Items Measured at Fair Value on a Nonrecurring Basis

The Company measures certain assets and liabilities at fair value on a non-recurring basis. As these nonrecurring fair value measurements are generally determined using unobservable inputs, these fair value measurements are classified within Level 3 of the fair value hierarchy. The Company utilized a third-party to assist in the Level 3 fair value estimates of other intangible assets for recent acquisitions (see Note 2) and goodwill of the Medical reporting unit (see Note 5). The estimated fair values of these assets were based on third-party valuations and management’s estimates, generally utilizing income and market approaches. As of June 30, 2023, and December 31, 2022, there were no other significant assets or liabilities measured at fair value on a non-recurring basis.

Items Not Carried at Fair Value

The Company uses an income valuation technique to measure the fair values of its debt instruments by converting amounts of future cash flows to a single present value amount using rates based on current market expectations (Level 2 inputs). As of June 30, 2023, and December 31, 2022, the carrying values of the indebtedness under the Company’s Second Amended and Restated Credit Agreement were not materially different than the estimated fair values because the interest rates on variable rate debt approximated rates currently available to the Company (see Note 6).

Note 11 – Equity

In December 2020, the Board of Directors of Gentherm Incorporated (“Board of Directors”) authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150,000 of its issued and outstanding common stock over a three-year period, expiring December 15, 2023.

20

Repurchases may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. Any such repurchases may be executed using open market purchases, privately negotiated agreements or other transactions. Repurchases may be funded from cash on hand, available borrowings or proceeds from potential debt or other capital markets sources. During the three and six months ended June 30, 2023, the Company repurchased $9,996 and $19,993, respectively, of shares under the 2020 Stock Repurchase Program with an average price paid per share of $59.71 and $59.49, respectively. The 2020 Stock Repurchase Program had $110,007 of repurchase authorization remaining as of June 30, 2023.

Note 12 – Reclassifications Out of Accumulated Other Comprehensive Loss

Reclassification adjustments and other activities impacting Accumulated other comprehensive loss during the three and six months ended June 30, 2023 and 2022 were as follows:

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  | Commodity Hedge Derivatives |  |  | Total |
Balance at March 31, 2023 |  | $ | (1,063 | ) |  | $ | (40,014 | ) |  | $ | 4,976 |  |  | $ | — |  |  | $ | (36,101 | )
Other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (3,611 | ) |  |  | 4,889 |  |  |  | — |  |  |  | 1,278 |
Income tax effect of other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | 23 |  |  |  | (1,065 | ) |  |  | — |  |  |  | (1,042 | )
Amounts reclassified from accumulated other comprehensive loss into net (loss) income |  |  | 6 |  |  |  | — |  |  |  | (1,984 | ) | a |  | — |  | a |  | (1,978 | )
Income taxes reclassified into net (loss) income |  |  | (2 | ) |  |  | — |  |  |  | 432 |  |  |  | — |  |  |  | 430 |
Net current period other comprehensive income (loss) |  |  | 4 |  |  |  | (3,588 | ) |  |  | 2,272 |  |  |  | — |  |  |  | (1,312 | )
Balance at June 30, 2023 |  | $ | (1,059 | ) |  | $ | (43,602 | ) |  | $ | 7,248 |  |  | $ | — |  |  | $ | (37,413 | )

(a)
The amounts reclassified from Accumulated other comprehensi ve loss w ere included in Cost of sales.

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  | Commodity Hedge Derivatives |  |  | Total |
Balance at March 31, 2022 |  | $ | (2,864 | ) |  | $ | (43,482 | ) |  | $ | 618 |  |  | $ | — |  |  | $ | (45,728 | )
Other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (22,458 | ) |  |  | 17 |  |  |  | — |  |  |  | (22,441 | )
Income tax effect of other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (242 | ) |  |  | (4 | ) |  |  | — |  |  |  | (246 | )
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | 35 |  |  |  | — |  |  |  | (333 | ) | a |  | — |  | a |  | (298 | )
Income taxes reclassified into net income |  |  | (8 | ) |  |  | — |  |  |  | 73 |  |  |  | — |  |  |  | 65 |
Net current period other comprehensive income (loss) |  |  | 27 |  |  |  | (22,700 | ) |  |  | (247 | ) |  |  | — |  |  |  | (22,920 | )
Balance at June 30, 2022 |  | $ | (2,837 | ) |  | $ | (66,182 | ) |  | $ | 371 |  |  | $ | — |  |  | $ | (68,648 | )

(a)
The amounts reclassified from Accumulated other comprehensive loss were included in Cost of sales.

21

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  | Commodity Hedge Derivatives |  |  | Total |
Balance at December 31, 2022 |  | $ | (1,067 | ) |  | $ | (48,269 | ) |  | $ | 2,847 |  |  | $ | — |  |  | $ | (46,489 | )
Other comprehensive income before reclassifications |  |  | — |  |  |  | 4,580 |  |  |  | 8,631 |  |  |  | — |  |  |  | 13,211 |
Income tax effect of other comprehensive income before reclassifications |  |  | — |  |  |  | 87 |  |  |  | (1,880 | ) |  |  | — |  |  |  | (1,793 | )
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | 12 |  |  |  | — |  |  |  | (3,043 | ) | a |  | — |  | a |  | (3,031 | )
Income taxes reclassified into net income |  |  | (4 | ) |  |  | — |  |  |  | 693 |  |  |  | — |  |  |  | 689 |
Net current period other comprehensive income |  |  | 8 |  |  |  | 4,667 |  |  |  | 4,401 |  |  |  | — |  |  |  | 9,076 |
Balance at June 30, 2023 |  | $ | (1,059 | ) |  | $ | (43,602 | ) |  | $ | 7,248 |  |  | $ | — |  |  | $ | (37,413 | )

(a)
The amounts reclassified from Accumulated other comprehensive loss were included in Cost of sales.

|  | Defined Benefit Pension Plans |  |  | Foreign Currency Translation Adjustments |  |  | Foreign Currency Hedge Derivatives |  |  | Commodity Hedge Derivatives |  |  | Total |
Balance at December 31, 2021 |  | $ | (2,893 | ) |  | $ | (34,188 | ) |  | $ | 154 |  |  | $ | 5 |  |  | $ | (36,922 | )
Other comprehensive (loss) income before reclassifications |  |  | — |  |  |  | (31,612 | ) |  |  | 780 |  |  |  | 13 |  |  |  | (30,819 | )
Income tax effect of other comprehensive loss before reclassifications |  |  | — |  |  |  | (382 | ) |  |  | (183 | ) |  |  | (3 | ) |  |  | (568 | )
Amounts reclassified from accumulated other comprehensive loss into net income |  |  | 70 |  |  |  | — |  |  |  | (486 | ) | a |  | (19 | ) | a |  | (435 | )
Income taxes reclassified into net income |  |  | (14 | ) |  |  | — |  |  |  | 106 |  |  |  | 4 |  |  |  | 96 |
Net current period other comprehensive income (loss) |  |  | 56 |  |  |  | (31,994 | ) |  |  | 217 |  |  |  | (5 | ) |  |  | (31,726 | )
Balance at June 30, 2022 |  | $ | (2,837 | ) |  | $ | (66,182 | ) |  | $ | 371 |  |  | $ | — |  |  | $ | (68,648 | )

(a)
The amounts reclassified from Accumulated other compreh ensive loss were included in Cost of sales.

The Company expects all of the existing gains and losses related to foreign currency derivatives reported in Accumulated other comprehensive loss as of June 30, 2023 to be reclassified into earnings during the next twelve months. See Note 9 for additional information about derivative financial instruments and the effects from reclassification to Net (loss) income.

Note 13 – Income Taxes

At the end of each interim period, the Company makes an estimate of the annual expected effective income tax rate and applies that rate to its ordinary year-to-date earnings or loss. The income tax provision or benefit related to unusual or infrequent items, if applicable, that will be separately reported or reported net of their related tax effects are individually computed and recognized in the interim period in which those items occur. In addition, the effect of changes in enacted tax laws or rates, tax status, judgment on the realizability of a beginning-of-the-year deferred tax asset in future years or income tax contingencies is recognized in the interim period in which the change occurs.

The computation of the annual expected effective income tax rate at each interim period requires certain estimates and assumptions including, but not limited to, the expected pre-tax income (or loss) for the year, projections of the proportion of income (and/or loss) earned and taxed in respective jurisdictions, permanent and temporary differences, and the likelihood of the realizability of deferred tax assets generated in the current year. Jurisdictions with a projected loss for the year for which no tax benefit can be recognized due to a valuation allowance are excluded from the estimated annual effective tax rate. The impact of such an exclusion could result in a higher or lower effective tax rate during a particular quarter, based upon the composition and timing of actual earnings compared to annual projections. The estimates used to compute the provision or benefit for income taxes may change as new events occur, additional information is obtained or as our tax environment changes. To the extent that the expected annual effective income tax rate changes, the effect of the change on prior interim periods is included in the income tax provision in the period in which the change in estimate occurs.

22

A summary of the provision for income taxes and the corresponding effective tax rate for the three and six months ended June 30, 2023 and 2022, is shown below:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Income tax expense |  | $ | 4,842 |  |  | $ | 3,919 |  |  | $ | 8,570 |  |  | $ | 8,214 |
Earnings before income tax |  | $ | 3,291 |  |  | $ | 10,991 |  |  | $ | 14,982 |  |  | $ | 27,033 |
Effective tax rate |  |  | 147.1 | % |  |  | 35.7 | % |  |  | 57.2 | % |  |  | 30.4 | %

Income tax expense was $4,842 for the three months ended June 30, 2023 on earnings before income tax of $3,291, representing an effective tax rate of 147.1 %. The pre-tax earnings included the effect of an impairment loss of $19,509 with a tax benefit of $2,423. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of the tax benefit related to the impairment loss, income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”) and an impact related to legal entity restructuring, partially offset by the impact of research and development credits in various jurisdictions.

Income tax expense was $3,919 for the three months ended June 30, 2022 on earnings before income tax of $10,991, representing an effective tax rate of 35.7 %. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects on equity vesting.

Income tax expense was $8,570 for the six months ended June 30, 2023 on earnings before income tax of $14,982, representing an effective tax rate of 57.2 %. The pre-tax earnings included the effect of an impairment loss of $19,509 with a tax benefit of $2,423. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the impact of the tax benefit related to the impairment loss, income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, the quarterly accrual for uncertain tax positions and an impact related to legal entity restructuring, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects of equity vesting.

Income tax expense was $8,214 for the six months ended June 30, 2022 on earnings before income tax of $27,033, representing an effective tax rate of 30.4 %. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, and the quarterly accrual for uncertain tax positions partially offset by the impact of certain favorable tax effects of equity vesting.

Note 14 – Segment Reporting

Segment information is used by management for making operating decisions for the Company. Management evaluates the performance of the Company’s segments based primarily on operating income or loss.

The Company’s reportable segments are as follows:

•
Automotive – this segment represents the design, development, manufacturing and sales of automotive climate comfort systems, automotive cable systems, lumbar and massage comfort solutions, valve systems, battery performance solutions, and automotive electronic and software systems.
•
Medical – this segment represents the results from our patient temperature management business within the medical industry.

The Corporate category includes unallocated costs related to our corporate headquarter activities, including selling, general and administrative costs and acquisition transaction costs, which do not meet the requirements for being classified as an operating segment.

23

The tables below present segment information about the reported Product revenues, Depreciation and amortization and Operating income (loss) of the Company for the three and six months ended June 30, 2023 and 2022.

Three Months Ended June 30, |  | Automotive |  |  | Medical |  |  | Corporate |  |  | Total |
2023 |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 361,533 |  |  | $ | 10,790 |  |  | $ | — |  |  | $ | 372,323 |
Depreciation and amortization |  |  | 11,221 |  |  |  | 896 |  |  |  | 427 |  |  | $ | 12,544 |
Operating income (loss) |  |  | 46,561 |  |  |  | (20,540 | ) |  |  | (21,700 | ) |  | $ | 4,321 |
2022 |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 249,152 |  |  | $ | 11,563 |  |  | $ | — |  |  | $ | 260,715 |
Depreciation and amortization |  |  | 8,197 |  |  |  | 558 |  |  |  | 305 |  |  | $ | 9,060 |
Operating income (loss) |  |  | 24,026 |  |  |  | (181 | ) |  |  | (16,110 | ) |  | $ | 7,735 |
Six Months Ended June 30, |  | Automotive |  |  | Medical |  |  | Corporate |  |  | Total |
2023 |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 714,225 |  |  | $ | 21,723 |  |  | $ | — |  |  | $ | 735,948 |
Depreciation and amortization |  |  | 23,511 |  |  |  | 1,874 |  |  |  | 692 |  |  | $ | 26,077 |
Operating income (loss) |  |  | 84,940 |  |  |  | (21,033 | ) |  |  | (41,912 | ) |  | $ | 21,995 |
2022 |  |  |  |  |  |  |  |  |  |  |  |
Product revenues |  | $ | 507,016 |  |  | $ | 21,356 |  |  | $ | — |  |  | $ | 528,372 |
Depreciation and amortization |  |  | 16,863 |  |  |  | 1,162 |  |  |  | 610 |  |  | $ | 18,635 |
Operating income (loss) |  |  | 55,301 |  |  |  | (1,032 | ) |  |  | (32,344 | ) |  | $ | 21,925 |

Automotive and Medical segment Product revenues by product category for the three and six months ended June 30, 2023 and 2022 were as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
Climate Control Seat |  | $ | 121,210 |  |  | $ | 96,488 |  |  | $ | 235,963 |  |  | $ | 199,222 |
Seat Heaters |  |  | 78,258 |  |  |  | 65,903 |  |  |  | 153,894 |  |  |  | 134,799 |
Steering Wheel Heaters |  |  | 38,958 |  |  |  | 28,951 |  |  |  | 75,305 |  |  |  | 57,687 |
Lumbar and Massage Comfort Solutions (a) |  |  | 37,604 |  |  |  | — |  |  |  | 76,342 |  |  |  | — |
Valve Systems (a) |  |  | 27,692 |  |  |  | — |  |  |  | 54,686 |  |  |  | — |
Automotive Cables |  |  | 20,243 |  |  |  | 19,280 |  |  |  | 40,463 |  |  |  | 41,325 |
Battery Performance Solutions |  |  | 19,587 |  |  |  | 17,451 |  |  |  | 39,896 |  |  |  | 35,064 |
Electronics |  |  | 9,323 |  |  |  | 10,278 |  |  |  | 20,293 |  |  |  | 21,106 |
Other Automotive |  |  | 8,658 |  |  |  | 10,801 |  |  |  | 17,383 |  |  |  | 17,813 |
Subtotal Automotive segment |  |  | 361,533 |  |  |  | 249,152 |  |  |  | 714,225 |  |  |  | 507,016 |
Medical segment (b) |  |  | 10,790 |  |  |  | 11,563 |  |  |  | 21,723 |  |  |  | 21,356 |
Total Company |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 735,948 |  |  | $ | 528,372 |

(a)
Represents Product revenues from Alfmeier (acquired on August 1, 2022) - (see Note 2)
(b)
Includes Product revenues of $1,672 and $2,951 for the three and six months ended June 30, 2023 from Dacheng (acquired on July 13, 2022) - (see Note 2)

24

Total P roduct revenues information by geographic area for the three and six months ended June 30, 2023 and 2022 is as follows (based on shipment destination):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
United States |  | $ | 138,319 |  |  | $ | 102,617 |  |  | $ | 279,771 |  |  | $ | 206,738 |
China |  |  | 53,872 |  |  |  | 31,391 |  |  |  | 100,526 |  |  |  | 69,744 |
South Korea |  |  | 29,995 |  |  |  | 23,706 |  |  |  | 58,733 |  |  |  | 44,881 |
Germany |  |  | 26,039 |  |  |  | 15,565 |  |  |  | 52,551 |  |  |  | 35,351 |
Czech Republic |  |  | 17,372 |  |  |  | 12,195 |  |  |  | 35,022 |  |  |  | 25,810 |
Japan |  |  | 12,867 |  |  |  | 12,886 |  |  |  | 28,089 |  |  |  | 24,702 |
Romania |  |  | 13,436 |  |  |  | 11,519 |  |  |  | 25,969 |  |  |  | 24,273 |
Slovakia |  |  | 12,712 |  |  |  | 8,987 |  |  |  | 24,308 |  |  |  | 17,360 |
Finland |  |  | 11,139 |  |  |  | 7,352 |  |  |  | 21,272 |  |  |  | 13,913 |
Mexico |  |  | 10,356 |  |  |  | 4,267 |  |  |  | 19,450 |  |  |  | 9,137 |
Other |  |  | 46,216 |  |  |  | 30,230 |  |  |  | 90,257 |  |  |  | 56,463 |
Total Non-U.S. |  |  | 234,004 |  |  |  | 158,098 |  |  |  | 456,177 |  |  |  | 321,634 |
Total Company |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 735,948 |  |  | $ | 528,372 |

25

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward-Looking Statements

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements represent our goals, beliefs, plans and expectations about our prospects for the future and other future events, such as: the expected light vehicle production in the Company’s key markets; the integration of recent acquisitions; the impact of macroeconomic and geopolitical conditions; the components of and our ability to execute our updated strategic plan; long-term consumer and technological trends in the Automotive industry and our related market opportunity for our existing and new products and technologies; the competitive landscape; the sufficiency of our cash balances and cash generated from operating, investing and financing activities for our future liquidity and capital resource needs; and our ability to finance sufficient working capital. Reference is made in particular to forward-looking statements included in this “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations”. Such statements may be identified by the use of forward-looking terminology such as “may”, “will”, “expect”, “believe”, “estimate”, “anticipate”, “intend”, “continue”, or similar terms, variations of such terms or the negative of such terms. The forward-looking statements included in this Report are made as of the date hereof or as of the date specified herein and are based on management’s reasonable expectations and beliefs. In making these statements we rely on assumptions and analysis based on our experience and perception of historical trends, current conditions and expected future developments, as well as other factors we consider appropriate under the circumstances. Such statements are subject to a number of assumptions, risks, uncertainties and other factors, which are set forth in “Item 1A. Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent reports filed with or furnished to the Securities and Exchange Commission, and which could cause actual results to differ materially from that described in the forward-looking statements. In addition, with reasonable frequency, we have entered into business combinations, acquisitions, divestitures, strategic investments and other significant transactions. Such forward-looking statements do not include the potential impact of any such transactions that may be completed after the date hereof, each of which may present material risks to the Company’s future business and financial results. Except as required by law, we expressly disclaim any obligation or undertaking to update any forward-looking statements to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

The following discussion and analysis should be read in conjunction with, and is qualified in its entirety by, our consolidated condensed financial statements and related notes thereto included elsewhere in this Report and our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.

Overview

Gentherm Incorporated is the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive and medical industries. Automotive products include variable temperature Climate Control Seats, heated automotive interior systems (including heated seats, steering wheels, armrests and other components), battery performance solutions, cable systems, lumbar and massage comfort solutions, valve systems, and other electronic devices. Our automotive products can be found on vehicles manufactured by nearly all the major original equipment manufacturers (“OEMs”) operating in North America and Europe, and several major OEMs in Asia. We operate in locations aligned with our major customers’ product strategies to provide locally enhanced design, integration and production capabilities. Medical products include patient temperature management systems. Our medical products can be found in hospitals throughout the world, primarily in the US, China, Germany and Brazil. The Company is also developing a number of new technologies and products that will help enable improvements to existing products, improve health, wellness and patient outcomes and will lead to new product applications for existing and new and adjacent markets.

Our sales are driven by the number of vehicles produced by the OEMs, which is ultimately dependent on consumer demand for automotive vehicles, our product content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. Historically, new vehicle demand and product content (i.e. vehicle features) have been driven by macroeconomic and other factors, such as interest rates, automotive manufacturer and dealer sales incentives, fuel prices, consumer confidence, employment levels, income growth trends and government and tax incentives. Vehicle content has also been driven by trends in consumer preferences, such as preferences for smart devices and features, personalized user experience, and comfort, health and wellness. Economic volatility or weakness, as well as geopolitical factors, in North America, Europe or Asia, have had and could result in a significant reduction in automotive sales and production by our customers, which have had and would have an adverse effect on our business, results of operations and financial condition. We believe our diversified OEM customer base and geographic revenue base, along with our flexible cost structure, have well positioned us to withstand the impact of industry downturns and benefit from industry upturns in the ordinary course. However, shifts in the mix of global automotive production to higher cost regions or to

26

vehicles that contain less of our product content as well as continuing production challenges and inflationary pressures could adversely impact our profitability. In addition, we may be adversely impacted by volatility or weakness in markets for hybrid or electric vehicles specifically. We believe our products offer certain advantages for hybrid and electric vehicles, including improved energy efficiency, and position us well to withstand changes in the volume mix between vehicles driven by internal combustion engines and hybrid and other electric vehicles. We believe our industry is increasingly progressing towards a focus on human comfort and health, which is evidenced by increasing adoption rates for comfort products. We believe that products we are developing, such as ClimateSense® and our acquisition of Alfmeier’s pneumatic comfort solutions, position us well to address trends in consumer preferences such as personalized user experience, comfort, health and wellness.

Recent Trends

Global Conditions

Since 2020, the global economy has experienced significant volatility and supply chain disruption, which has had a widespread adverse effect on the global automotive industry. These macroeconomic conditions have resulted in fluctuating demand and production disruptions, facility closures, labor shortages and work stoppages. In addition, global inflation has increased significantly beginning in 2021. Rising costs of materials, labor, equipment and other inputs used to manufacture and sell our products, including freight and logistics costs, have impacted, and may in the future impact, operating costs and operating results. We continue to employ measures to mitigate the impact of cost increases through identification of sourcing and manufacturing efficiencies where possible. However, we have been unable to fully mitigate or pass through the increases in our operating costs, which may continue in the future.

Although we are optimistic that the worst of the global macroeconomic volatility is in the past, the direct and indirect impacts on our markets, operations, and financial performance remain unpredictable. As a result of this continued uncertainty, there may still be impacts on our industry, operations, workforce, supply chains, distribution systems, and demand for our products in the future which cannot be reasonably estimated at this time.

On December 15, 2022, the European Union (“EU”) Member States formally adopted the EU’s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development Pillar Two Framework. The effective dates for different aspects of the directive are January 1, 2024, and January 1, 2025. A significant number of other countries are also implementing similar legislation. The Company is continuing to evaluate the potential impact on future periods of these tax regulations.

Fit-for-Growth 2.0

During the first half of 2023, we launched Fit-for-Growth 2.0 to execute our long-term strategy that includes a profitability improvement initiative with a plan to achieve high teens Adjusted EBITDA margin rate by 2026. Fit-for-Growth 2.0 is expected to deliver cost reductions through manufacturing productivity, manufacturing footprint optimization, value engineering, sourcing excellence and cost synergies from the Alfmeier acquisition. Additionally, the program will drive operating expense efficiency to leverage scale as we continue our growth path towards our target of over $2 billion dollars by 2026.

Acquisitions

On July 13, 2022, the Company completed the acquisition of Jiangmen Dacheng Medical Equipment Co. Ltd (“Dacheng”) and its wholly owned subsidiary, IOB Medical, Inc. Dacheng is a privately held manufacturer of medical materials and medical equipment, including patient temperature management solutions, for numerous local and international customers. The acquisition provided Gentherm Medical a local presence in China’s high-growth market for patient warming devices and other medical device products, and expanded overall manufacturing capacity to include a low-cost manufacturing site. The total consideration transferred was $35.0 million.

On August 1, 2022, the Company acquired 100% of the equity interests of Alfmeier Präzision SE (“Alfmeier”) a global leader in automotive lumbar and massage comfort solutions and a leading provider of advanced valve systems, integrated electronics and software. The acquisition further expanded the Company's value proposition beyond thermal in comfort, health, wellness, and energy efficiency and aligned well with global consumer demand for expanded offerings in vehicle passenger comfort. The total consideration for this acquisition was $170.7 million.

See Note 2, “Acquisitions” to the consolidated condensed financial statements included in this Report for additional information.

27

Impairments – Non-Automotive Electronics Business

On December 31, 2022, the Company approved a plan to exit its non-automotive electronics business to strengthen the Company’s core business and focus its resources and equipment with businesses and investments that are more strategic and profitable. The Company will continue to sell certain non-automotive electronics products until the exit is complete. During the year ended December 31, 2022, the Company recorded non-cash impairment charges of $9.4 million, $5.6 million and $0.7 million for write downs of inventory, intangible assets and property and equipment, respectively, within the Automotive segment.

During the three and six months ended June 30, 2023, the Company recorded non-cash impairment charges of $0.6 and $2.1 million for the write down of inventory within the Automotive segment. This charge is recorded in Cost of sales.

The Company is no longer pursuing a sale of the business and intends to wind-down the operations of the business by the end of 2023, subject to discussions with customers and suppliers.

Impairments - Medical Segment

As of December 31, 2022, the estimated fair value of the Medical reporting unit exceeded its carrying value by less than 10%. During the second quarter of 2023, the Company’s Medical reporting unit did not perform in-line with forecasted results primarily driven by slower than anticipated revenue growth. As a result, an indicator of impairment was identified and the Company performed an interim quantitative assessment as of June 30, 2023. The results of this quantitative analysis indicated the carrying value of the reporting unit exceeded the fair value of the reporting unit by $17.1 million, and accordingly an impairment expense was recorded for $19.5 million that includes the associated deferred tax effect.

The primary factors leading to the decline in value from the analysis performed at December 31, 2022 were a reduction in expected future cash flows, due to the Company re-evaluating our forecasted results and an increase in the discount rate which is based on the Medical reporting unit’s weighted average cost of capital. The decline in expected future cash flows resulted primarily from a reduction of forecasted revenue growth rates. If the Company’s revised expectation of revenue growth is not achieved or if the estimated growth rates are reduced because of new information or experience, the fair value of the Medical reporting unit could decrease, which could result in further impairment of goodwill.

Light Vehicle Production Volumes

Our sales are driven by the number of vehicles produced by the automotive manufacturers, which is ultimately dependent on consumer demand for automotive vehicles, and our content per vehicle, and other factors that may limit or otherwise impact production by us, our supply chain and our customers. According to the forecasting firm S&P Global Mobility (July 2023 release), global light vehicle production in the three and six months ended June 30, 2023 in the Company’s key markets of North America, Europe, China, Japan and Korea, as compared to the three and six months ended June 30, 2022, are shown below (in millions of units):

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | % Change |  |  | 2023 |  |  | 2022 |  |  | % Change |
North America |  |  | 4.1 |  |  |  | 3.5 |  |  |  | 14.9 | % |  |  | 8.0 |  |  |  | 7.1 |  |  |  | 12.2 | %
Europe |  |  | 4.5 |  |  |  | 4.0 |  |  |  | 14.3 | % |  |  | 9.2 |  |  |  | 7.9 |  |  |  | 16.1 | %
Greater China |  |  | 6.6 |  |  |  | 5.5 |  |  |  | 20.4 | % |  |  | 12.6 |  |  |  | 11.7 |  |  |  | 7.1 | %
Japan / South Korea |  |  | 3.1 |  |  |  | 2.5 |  |  |  | 25.3 | % |  |  | 6.3 |  |  |  | 5.2 |  |  |  | 21.0 | %
Total light vehicle production volume in key markets |  |  | 18.4 |  |  |  | 15.5 |  |  |  | 18.4 | % |  |  | 36.0 |  |  |  | 31.9 |  |  |  | 12.7 | %

The S&P Global Mobility (July 2023 release) forecasted light vehicle production volume in the Company’s key markets for full year 2023 to increase to 71.8 million units, a 6.2% increase from full year 2022 light vehicle production volumes. Forecasted light vehicle production volumes are a component of the data we use in forecasting future business. However, these forecasts generally are updated monthly, and future forecasts may be significantly different from period to period due to changes in macroeconomic conditions or matters specific to the automotive industry. Further, due to differences in regional product mix at our manufacturing facilities, as well as material production schedules from our customers for our products on specific vehicle programs, our future forecasted results do not directly correlate with the global and/or regional light vehicle production forecasts of S&P Global Mobility or other third-party sources.

28

New Business Awards

We believe that innovation is an important element to gaining market acceptance of our products and strengthening our market position. During the second quarter of 2023, we secured new automotive business awards totaling $670 million in the quarter. Automotive new business awards represent the aggregate projected lifetime revenue of new awards provided by our customers to Gentherm in the applicable period, with the value based on the price and volume projections received from each customer as of the award date. Although automotive new business awards are not firm customer orders, we believe that new business awards are an indicator of future revenue. New business awards are not projections of revenue or future business as of June 30, 2023, the date of this Report or any other date. Customer projections regularly change over time and we do not update our calculation of any new business award after the date initially communicated. Automotive new business awards in the second quarter 2023 also do not reflect, in particular, the impact of macroeconomic and geopolitical challenges on future business. Revenues resulting from automotive new business awards also are subject to additional risks and uncertainties that are included in this Report or incorporated by reference in “Forward-Looking Statements” above.

Stock Repurchase Program

In December 2020, the Board of Directors authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding Common Stock over a three-year period, expiring December 15, 2023. Repurchases under the 2020 Stock Repurchase Program may be made, from time to time, in amounts and at prices the Company deems appropriate, subject to market conditions, applicable legal requirements, debt covenants and other considerations. During the three and six months ended June 30, 2023, the Company repurchased $10.0 million and $20.0 million, respectively, of shares under the 2020 Stock Repurchase Program with an average price paid per share of $59.71 and $59.49, respectively. The 2020 Stock Repurchase Program had $110.0 million repurchase authorization remaining as of June 30, 2023.

Reportable Segments

The Company has two reportable segments for financial reporting purposes: Automotive and Medical.

See Note 14, “Segment Reporting” to the consolidated condensed financial statements included in this Report for a description of our reportable segments as well as their proportional contribution to the Company’s reported product revenues and operating income (loss). The financial information used by our chief operating decision maker to assess operating performance and allocate resources is based on these reportable segments.

Consolidated Results of Operations

The results of operations for the three and six months ended June 30, 2023 and 2022, in thousands, were as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |  |  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Product revenues |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 111,608 |  |  | $ | 735,948 |  |  | $ | 528,372 |  |  | $ | 207,576 |
Cost of sales |  |  | 284,335 |  |  |  | 201,338 |  |  |  | (82,997 | ) |  |  | 566,830 |  |  |  | 404,882 |  |  |  | (161,948 | )
Gross margin |  |  | 87,988 |  |  |  | 59,377 |  |  |  | 28,611 |  |  |  | 169,118 |  |  |  | 123,490 |  |  |  | 45,628 |
Operating expenses: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net research and development expenses |  |  | 24,696 |  |  |  | 19,325 |  |  |  | (5,371 | ) |  |  | 49,841 |  |  |  | 39,759 |  |  |  | (10,082 | )
Selling, general and administrative expenses |  |  | 38,418 |  |  |  | 31,943 |  |  |  | (6,475 | ) |  |  | 75,460 |  |  |  | 61,251 |  |  |  | (14,209 | )
Impairment of goodwill |  |  | 19,509 |  |  |  | — |  |  |  | (19,509 | ) |  |  | 19,509 |  |  |  | — |  |  |  | (19,509 | )
Restructuring expenses |  |  | 1,044 |  |  |  | 374 |  |  |  | (670 | ) |  |  | 2,313 |  |  |  | 555 |  |  |  | (1,758 | )
Total operating expenses |  |  | 83,667 |  |  |  | 51,642 |  |  |  | (32,025 | ) |  |  | 147,123 |  |  |  | 101,565 |  |  |  | (45,558 | )
Operating income |  |  | 4,321 |  |  |  | 7,735 |  |  |  | (3,414 | ) |  |  | 21,995 |  |  |  | 21,925 |  |  |  | 70 |
Interest expense, net |  |  | (1,932 | ) |  |  | (1,430 | ) |  |  | (502 | ) |  |  | (6,076 | ) |  |  | (1,999 | ) |  |  | (4,077 | )
Foreign currency gain (loss) |  |  | 346 |  |  |  | 4,552 |  |  |  | (4,206 | ) |  |  | (1,723 | ) |  |  | 6,769 |  |  |  | (8,492 | )
Other income |  |  | 556 |  |  |  | 134 |  |  |  | 422 |  |  |  | 786 |  |  |  | 338 |  |  |  | 448 |
Earnings before income tax |  |  | 3,291 |  |  |  | 10,991 |  |  |  | (7,700 | ) |  |  | 14,982 |  |  |  | 27,033 |  |  |  | (12,051 | )
Income tax expense |  |  | 4,842 |  |  |  | 3,919 |  |  |  | (923 | ) |  |  | 8,570 |  |  |  | 8,214 |  |  |  | (356 | )
Net (loss) income |  | $ | (1,551 | ) |  | $ | 7,072 |  |  | $ | (8,623 | ) |  | $ | 6,412 |  |  | $ | 18,819 |  |  | $ | (12,407 | )

29

Product revenues by product category, in thousands, for the three and six months ended June 30, 2023 and 2022, were as follows:

|  | Three Months Ended June 30, |  |  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | $ Change |  |  | % Change |  |  | 2023 |  |  | 2022 |  |  | $ Change |  |  | % Change |
Climate Control Seat |  | $ | 121,210 |  |  | $ | 96,488 |  |  | $ | 24,722 |  |  |  | 25.6 | % |  | $ | 235,963 |  |  | $ | 199,222 |  |  | $ | 36,741 |  |  |  | 18.4 | %
Seat Heaters |  |  | 78,258 |  |  |  | 65,903 |  |  |  | 12,355 |  |  |  | 18.7 | % |  |  | 153,894 |  |  |  | 134,799 |  |  |  | 19,095 |  |  |  | 14.2 | %
Steering Wheel Heaters |  |  | 38,958 |  |  |  | 28,951 |  |  |  | 10,007 |  |  |  | 34.6 | % |  |  | 75,305 |  |  |  | 57,687 |  |  |  | 17,618 |  |  |  | 30.5 | %
Lumbar and Massage Comfort Solutions |  |  | 37,604 |  |  |  | — |  |  |  | 37,604 |  |  |  | 100.0 | % |  |  | 76,342 |  |  |  | — |  |  |  | 76,342 |  |  |  | 100.0 | %
Valve Systems |  |  | 27,692 |  |  |  | — |  |  |  | 27,692 |  |  |  | 100.0 | % |  |  | 54,686 |  |  |  | — |  |  |  | 54,686 |  |  |  | 100.0 | %
Automotive Cables |  |  | 20,243 |  |  |  | 19,280 |  |  |  | 963 |  |  |  | 5.0 | % |  |  | 40,463 |  |  |  | 41,325 |  |  |  | (862 | ) |  |  | (2.1 | )%
Battery Performance Solutions |  |  | 19,587 |  |  |  | 17,451 |  |  |  | 2,136 |  |  |  | 12.2 | % |  |  | 39,896 |  |  |  | 35,064 |  |  |  | 4,832 |  |  |  | 13.8 | %
Electronics |  |  | 9,323 |  |  |  | 10,278 |  |  |  | (955 | ) |  |  | (9.3 | )% |  |  | 20,293 |  |  |  | 21,106 |  |  |  | (813 | ) |  |  | (3.9 | )%
Other Automotive |  |  | 8,658 |  |  |  | 10,801 |  |  |  | (2,143 | ) |  |  | (19.8 | )% |  |  | 17,383 |  |  |  | 17,813 |  |  |  | (430 | ) |  |  | (2.4 | )%
Subtotal Automotive segment |  |  | 361,533 |  |  |  | 249,152 |  |  |  | 112,381 |  |  |  | 45.1 | % |  |  | 714,225 |  |  |  | 507,016 |  |  |  | 207,209 |  |  |  | 40.9 | %
Medical segment |  |  | 10,790 |  |  |  | 11,563 |  |  |  | (773 | ) |  |  | (6.7 | )% |  |  | 21,723 |  |  |  | 21,356 |  |  |  | 367 |  |  |  | 1.7 | %
Total Company |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 111,608 |  |  |  | 42.8 | % |  | $ | 735,948 |  |  | $ | 528,372 |  |  | $ | 207,576 |  |  |  | 39.3 | %

Product Revenues

Below is a summary of our product revenues, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |  |  |  | Automotive Volume |  |  | FX |  |  | Acquisitions |  |  | Pricing / Other |  |  | Total |
Product revenues |  | $ | 372,323 |  |  | $ | 260,715 |  |  | $ | 111,608 |  |  |  | $ | 48,938 |  |  | $ | (1,656 | ) |  | $ | 66,967 |  |  | $ | (2,641 | ) |  | $ | 111,608 |

Product revenues for the three months ended June 30, 2023 increased 42.8% as compared to the three months ended June 30, 2022. The increase in product revenues is due to favorable volumes in all product lines within the Automotive segment except Electronics and Other Automotive, and the inclusion of sales from Alfmeier and Dacheng since the acquisitions, partially offset by unfavorable foreign currency impacts. Currency impacts included unfavorable impacts primarily from the Chinese Renminbi and Korean Won, partially offset by favorable impacts from the Euro.

Below is a summary of our product revenues, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |  |  |  | Automotive Volume |  |  | FX |  |  | Acquisitions |  |  | Pricing / Other |  |  | Total |
Product revenues |  | $ | 735,948 |  |  | $ | 528,372 |  |  | $ | 207,576 |  |  |  | $ | 85,742 |  |  | $ | (9,787 | ) |  | $ | 133,978 |  |  | $ | (2,357 | ) |  | $ | 207,576 |

Product revenues for the six months ended June 30, 2023 increased 39.3% as compared to the six months ended June 30, 2022. The increase in product revenues is due to favorable volumes in all product lines within the Automotive segment except Electronics, Automotive Cables and Other Automotive, the inclusion of sales from Alfmeier and Dacheng since the acquisitions, and the negotiation of lower annual price reductions and cost recoveries from customers, partially offset by unfavorable foreign currency impacts, primarily related to the Euro, Chinese Renminbi, Korean Won, and Japanese Yen.

Cost of Sales

Below is a summary of our cost of sales and gross margin, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |  |  |  | Automotive Volume |  |  | Operational Performance |  |  | FX |  |  | Acquisitions and Other |  |  | Total |
Cost of sales |  | $ | 284,335 |  |  | $ | 201,338 |  |  | $ | (82,997 | ) |  |  | $ | (29,479 | ) |  | $ | 10,352 |  |  | $ | (791 | ) |  | $ | (63,079 | ) |  | $ | (82,997 | )
Gross margin |  | $ | 87,988 |  |  | $ | 59,377 |  |  | $ | 28,611 |  |  |  | $ | 19,459 |  |  | $ | 6,647 |  |  | $ | (2,448 | ) |  | $ | 4,953 |  |  | $ | 28,611 |
Gross margin - Percentage of product revenues |  |  | 23.6 | % |  |  | 22.8 | % |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

30

Cost of sales for the three months ended June 30, 2023 increased 41.2% as compared to the three months ended June 30, 2022. The increase in cost of sales is primarily due to increased volumes in our Automotive segment, the inclusion of expenses from the acquired businesses, inflation associated with wages, a non-automotive electronics inventory charge related to the exit of the business, higher quality costs, and unfavorable foreign currency impacts primarily attributable to the Euro and Mexican Peso. These increases were partially offset by favorable foreign currency impacts primarily attributable to the Chinese Renminbi, Ukrainian Hryvnia, and Korean Won, and lower freight costs.

Below is a summary of our cost of sales and gross margin, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |  |  |  | Variance Due To: |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |  |  |  | Automotive Volume |  |  | Operational Performance |  |  | FX |  |  | Acquisitions and Other |  |  | Total |
Cost of sales |  | $ | 566,830 |  |  | $ | 404,882 |  |  | $ | (161,948 | ) |  |  | $ | (51,534 | ) |  | $ | 14,097 |  |  | $ | 3,536 |  |  | $ | (128,047 | ) |  | $ | (161,948 | )
Gross margin |  | $ | 169,118 |  |  | $ | 123,490 |  |  | $ | 45,628 |  |  |  | $ | 34,208 |  |  | $ | 8,281 |  |  | $ | (6,251 | ) |  | $ | 9,390 |  |  | $ | 45,628 |
Gross margin - Percentage of product revenues |  |  | 23.0 | % |  |  | 23.4 | % |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |

Cost of sales for the six months ended June 30, 2023 increased 40.0% as compared to the six months ended June 30, 2022. The increase in cost of sales is primarily due to increased volumes in our Automotive segment, the inclusion of expenses from the acquired businesses, inflation associated with wages and material costs, a non-automotive electronics inventory charge related to the exit of the business, higher quality costs, and unfavorable foreign currency impacts primarily attributable to the Mexican Peso. These increases were partially offset by favorable foreign currency impacts primarily attributable to the Euro, Chinese Renminbi, Ukrainian Hryvnia, and Korean Won, and lower freight costs.

Net Research and Development Expenses

Below is a summary of our net research and development expenses, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Research and development expenses |  | $ | 30,737 |  |  | $ | 24,334 |  |  | $ | (6,403 | )
Reimbursed research and development expenses |  |  | (6,041 | ) |  |  | (5,009 | ) |  |  | 1,032 |
Net research and development expenses |  | $ | 24,696 |  |  | $ | 19,325 |  |  | $ | (5,371 | )
Percentage of product revenues |  |  | 6.6 | % |  |  | 7.4 | % |  |  |

Net research and development expenses for the three months ended June 30, 2023 increased 27.8% as compared to the three months ended June 30, 2022. The increase in net research and development expenses is primarily related to the inclusion of net expenses from Alfmeier and lower customer reimbursements, excluding those from Alfmeier.

Below is a summary of our net research and development expenses, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Research and development expenses |  | $ | 62,486 |  |  | $ | 48,237 |  |  | $ | (14,249 | )
Reimbursed research and development expenses |  |  | (12,645 | ) |  |  | (8,478 | ) |  |  | 4,167 |
Net research and development expenses |  | $ | 49,841 |  |  | $ | 39,759 |  |  | $ | (10,082 | )
Percentage of product revenues |  |  | 6.8 | % |  |  | 7.5 | % |  |  |

Net research and development expenses for the six months ended June 30, 2023 increased 25.4% as compared to the six months ended June 30, 2022. The increase in net research and development expenses is primarily related to the inclusion of net expenses from Alfmeier, increased investments to support new program wins, and lower customer reimbursements, excluding those from Alfmeier.

31

Selling, General and Administrative Expenses

Below is a summary of our selling, general and administrative expenses, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Selling, general and administrative expenses |  | $ | 38,418 |  |  | $ | 31,943 |  |  | $ | (6,475 | )
Percentage of product revenues |  |  | 10.3 | % |  |  | 12.3 | % |  |  |

Selling, general and administrative expenses for the three months ended June 30, 2023 increased 20.3% as compared to the three months ended June 30, 2022. The increase in selling, general and administrative expenses is primarily related to the inclusion of expenses from acquired businesses and higher compensation expenses.

Below is a summary of our selling, general and administrative expenses, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Selling, general and administrative expenses |  | $ | 75,460 |  |  | $ | 61,251 |  |  | $ | (14,209 | )
Percentage of product revenues |  |  | 10.3 | % |  |  | 11.6 | % |  |  |

Selling, general and administrative expenses for the six months ended June 30, 2023 increased 23.2% as compared to the six months ended June 30, 2022. The increase in selling, general and administrative expenses is primarily related to the inclusion of expenses from acquired businesses and higher compensation expenses.

Impairment of Intangible Assets and Property and Equipment

Below is a summary of our impairment of intangible assets and property and equipment, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Impairment of goodwill |  | $ | 19,509 |  |  | $ | — |  |  | $ | (19,509 | )

Impairment of intangible assets and property and equipment for the three months ended June 30, 2023 related to the recorded Medical reporting unit goodwill impairment.

Below is a summary of our impairment of intangible assets and property and equipment, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Impairment of goodwill |  | $ | 19,509 |  |  | $ | — |  |  | $ | (19,509 | )

Impairment of intangible assets and property and equipment for the six months ended June 30, 2023 related to the recorded Medical reporting unit goodwill impairment.

Restructuring Expenses

Below is a summary of our restructuring expenses, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Restructuring expenses |  | $ | 1,044 |  |  | $ | 374 |  |  | $ | (670 | )

32

During the three months ended June 30, 2023, the Company recognized expenses of $0.3 million for employee separation costs and $0.7 million for other costs. These restructuring expenses primarily relate to discrete restructuring actions focused on the reduction of global overhead expenses.

During the three months ended June 30, 2022, the Company recognized expenses of $0.0 million for employee separation costs and $0.4 million for other costs.

Below is a summary of our restructuring expenses, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Restructuring expenses |  | $ | 2,313 |  |  | $ | 555 |  |  | $ | (1,758 | )

During the six months ended June 30, 2023, the Company recognized expenses of $1.5 million for employee separation costs and $0.8 million for other costs. These restructuring expenses primarily relate to discrete restructuring actions focused on the reduction of global overhead expenses.

During the six months ended June 30, 2022, the Company recognized expenses of $0.1 million for employee separation costs and $0.5 million for other costs.

Interest Expense, net

Below is a summary of our interest expense, net, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Interest expense, net |  | $ | (1,932 | ) |  | $ | (1,430 | ) |  | $ | (502 | )

Interest expense, net for the three months ended June 30, 2023 increased 35.1% as compared to the three months ended June 30, 2022. The increase is primarily related to a higher balance on our revolving credit agreement during the three months ended June 30, 2023, as compared to the three months ended June 30, 2022, partially offset by the mark to market benefit of the Company’s interest rate swap during the three months ended June 30, 2023.

Below is a summary of our interest expense, net, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Interest expense, net |  | $ | (6,076 | ) |  | $ | (1,999 | ) |  | $ | (4,077 | )

Interest expense, net for the six months ended June 30, 2023 increased 204.0% as compared to the six months ended June 30, 2022. The increase is primarily related to a higher balance on our revolving credit agreement during the six months ended June 30, 2023, as compared to the six months ended June 30, 2022, partially offset by the mark to market benefit of the Company’s interest rate swap during the six months ended June 30, 2023. See Note 6, "Debt," to the consolidated condensed financial statements included in this Report for additional information.

Foreign Currency (Loss) Gain

Below is a summary of our foreign currency gain, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Foreign currency gain |  | $ | 346 |  |  | $ | 4,552 |  |  | $ | (4,206 | )

Foreign currency gain for the three months ended June 30, 2023 included net realized foreign currency loss of $0.4 million and net unrealized foreign currency gain of $0.7 million.

33

Foreign currency gain for the three months ended June 30, 2022 primarily included net realized foreign currency gain of $0.5 million and net unrealized foreign currency gain of $4.0 million.

Below is a summary of our foreign currency (loss) gain, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Foreign currency (loss) gain |  | $ | (1,723 | ) |  | $ | 6,769 |  |  | $ | (8,492 | )

Foreign currency loss for the six months ended June 30, 2023 included net realized foreign currency gain of $3.4 million and net unrealized foreign currency loss of $5.1 million.

Foreign currency gain for the six months ended June 30, 2022 primarily included net realized foreign currency gain of $0.4 million and net unrealized foreign currency gain of $6.4 million.

Other Income

Below is a summary of our other income, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Other income |  | $ | 556 |  |  | $ | 134 |  |  | $ | 422 |

Other income for the three months ended June 30, 2023 increased as compared to the three months ended June 30, 2022. The increase in Other income is due to an increase in miscellaneous income.

Below is a summary of our other income, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Other income |  | $ | 786 |  |  | $ | 338 |  |  | $ | 448 |

Other income for the six months ended June 30, 2023 increased as compared to the six months ended June 30, 2022. The increase in Other income is due to an increase in miscellaneous income.

Income Tax Expense

Below is a summary of our income tax expense, in thousands, for the three months ended June 30, 2023 and 2022:

|  | Three Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Income tax expense |  | $ | 4,842 |  |  | $ | 3,919 |  |  | $ | (923 | )

Income tax expense was $4.8 million for the three months ended June 30, 2023, on earnings before income tax of $3.3 million, representing an effective tax rate of 147.1 %. The pre-tax earnings included the effect of an impairment loss of $19.5 million with a tax benefit of $2.4 million. Adjusted for the impairment impacts, the effective rate was 31.9%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of the tax benefit related to the impairment loss, income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the global intangible low-tax income (“GILTI”) and an impact related to legal entity restructuring, partially offset by the impact of research and development credits in various jurisdictions.

Income tax expense was $3.9 million for the three months ended June 30, 2022 on earnings before income tax of $11.0 million representing an effective tax rate of 35.7%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the increase of accruals for uncertain tax positions partially offset by the impact of certain favorable tax effects on equity vesting.

34

Below is a summary of our income tax expense, in thousands, for the six months ended June 30, 2023 and 2022:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |  |  | Favorable / (Unfavorable) |
Income tax expense |  | $ | 8,570 |  |  | $ | 8,214 |  |  | $ | (356 | )

Income tax expense was $8.6 million for the six months ended June 30, 2023, on earnings before income tax of $15.0 million, representing an effective tax rate of 57.2 %. The pre-tax earnings included the effect of an impairment loss of $19.5 million with a tax benefit of $2.4 million. Adjusted for the impairment impacts, the effective rate was 31.9%. The effective tax rate differed from the U.S. Federal statutory rate of 21% primarily due to the impact of the tax benefit related to the impairment loss, impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of GILTI, the increase of accruals for uncertain tax positions and an impact related to legal entity restructuring, partially offset by the impact of research and development credits in various jurisdictions and certain favorable tax effects of equity vesting.

Income tax expense was $8.2 million for the six months ended June 30, 2022 on earnings before income tax of $27.0 million representing an effective tax rate of 30.4%. The effective tax rate differed from the U.S. Federal statutory rate of 21.0% primarily due to the impact of income taxes on foreign earnings taxed at rates varying from the U.S. statutory rate, the unfavorable impact of the GILTI, and the increase of accruals for uncertain tax positions partially offset by the impact of certain favorable tax effects of equity vesting.

Liquidity and Capital Resources

Overview

Our primary sources of liquidity and capital resources are cash flows from operations and borrowings available under our Second Amended and Restated Credit Agreement. Our cash requirements consist principally of working capital, capital expenditures, research and development, operating lease payments, income tax payments and general corporate purposes. We generally reinvest available cash flows from operations into our business, while opportunistically utilizing our authorized stock repurchase program. Further, we continuously evaluate acquisition and investment opportunities that will enhance our business strategies.

As of June 30, 2023, the Company had $168.7 million of cash and cash equivalents and $282.7 million of availability under our Second Amended and Restated Credit Agreement. We may issue debt or equity securities, which may provide an additional source of liquidity. However, there can be no assurance equity or debt financing will be available to us when we need it or, if available, the terms will be satisfactory to us and not dilutive to our then-current shareholders.

We continue to expect to be able to move funds between different countries to manage our global liquidity needs without material adverse tax implications, subject to current monetary policies and the terms of the Second Amended and Restated Credit Agreement. We utilize a combination of strategies, including dividends, cash pooling arrangements, intercompany loan repayments and other distributions and advances to provide the funds necessary to meet our global liquidity needs. There are no significant restrictions on the ability of our subsidiaries to pay dividends or make other distributions to Gentherm Incorporated. As of June 30, 2023, the Company’s cash and cash equivalents held by our non-U.S. subsidiaries totaled approximately $117.8 million. If additional non-U.S. cash was needed for our U.S. operations, we may be required to accrue and pay withholding if we were to distribute such funds from non-U.S. subsidiaries to the U.S.; however, based on our current liquidity needs and strategies, we do not anticipate a need to accrue and pay such additional amounts.

We currently believe that our cash and cash equivalents, borrowings available under our Second Amended and Restated Credit Agreement and receivables factoring arrangements, and cash flows from operations will be adequate to meet anticipated cash requirements for at least the next twelve months and the foreseeable future.

35

Cash and Cash Flows

The following table represents our cash and cash equivalents, in thousands:

|  | Six Months Ended June 30, |
|  | 2023 |  |  | 2022 |
Cash and cash equivalents at beginning of period |  | $ | 153,891 |  |  | $ | 190,606 |
Net cash provided by (used in) operating activities |  |  | 58,612 |  |  |  | (3,686 | )
Net cash used in investing activities |  |  | (6,776 | ) |  |  | (15,717 | )
Net cash used in financing activities |  |  | (39,356 | ) |  |  | (5,145 | )
Foreign currency effect on cash and cash equivalents |  |  | 2,300 |  |  |  | (8,800 | )
Cash and cash equivalents at end of period |  | $ | 168,671 |  |  | $ | 157,258 |

Cash Flows From Operating Activities

Net cash provided by operating activities totaled $58.6 million during the six months ended June 30, 2023 primarily reflecting net income of $6.4 million, $19.5 million for non-cash goodwill impairment, $32.0 million for non-cash charges for depreciation, amortization, stock based compensation and loss on disposition of property, non-cash charges of $1.9 million for inventory provisions, and $1.9 million related to changes in assets and liabilities, partially offset by non-cash charges of $2.8 million for deferred income taxes.

Cash Flows From Investing Activities

Net cash used in investing activities was $6.8 million during the six months ended June 30, 2023, reflecting purchases of property and equipment of $13.7 million and an investment in Carrar of $0.5 million, partially offset by proceeds from deferred purchase price of factored receivables of $7.4 million.

Cash Flows From Financing Activities

Net cash used in financing activities was $39.4 million during the six months ended June 30, 2023, reflecting $20.0 million paid to repurchase common stock, $17.0 million of debt repayments and $2.7 million paid for employee taxes related to the net settlement of restricted stock units that vested during the year, partially offset by the proceeds from the exercise of Common Stock options totaling $0.3 million.

Debt

The following table summarizes the Company’s debt, in thousands, as of June 30, 2023 and December 31, 2022:

|  | June 30, 2023 |  |  | December 31, 2022 |
|  | Interest Rate |  |  | Principal Balance |  |  | Interest Rate |  |  | Principal Balance |
Credit Agreement: |  |  |  |  |  |  |  |  |  |  |  |
Revolving Credit Facility (U.S. Dollar denominations) |  |  | 6.58 | % |  | $ | 217,000 |  |  |  | 5.80 | % |  | $ | 232,000 |
Other loans |  |  | 3.90 | % |  |  | 269 |  |  | 3.89% - 5.21% |  |  |  | 2,011 |
Finance leases |  | N/A |  |  |  | 856 |  |  | N/A |  |  |  | 1,085 |
Total debt |  |  |  |  |  | 218,125 |  |  |  |  |  |  | 235,096 |
Current maturities |  |  |  |  |  | (684 | ) |  |  |  |  |  | (2,443 | )
Long-term debt, less current maturities |  |  |  |  | $ | 217,441 |  |  |  |  |  | $ | 232,653 |

36

Credit Agreement

Gentherm, together with certain of its subsidiaries, maintain a revolving credit note (the “Revolving Credit Facility”) under its Second Amended and Restated Credit Agreement (the “Second Amended and Restated Credit Agreement”) with a consortium of lenders and Bank of America, N.A. as administrative agent. The Second Amended and Restated Credit Agreement was entered into on June 10, 2022 and amended and restated in its entirety the Amended and Restated Credit Agreement dated June 27, 2019, by and among Gentherm, certain of its direct and indirect subsidiaries, the lenders party thereto and the Agent. The Second Amended and Restated Credit Agreement has a maximum borrowing capacity of $500 million and matures on June 10, 2027. The Second Amended and Restated Credit Agreement contains covenants, that, among other things, (i) prohibit or limit the ability of the borrowers and any material subsidiary to incur additional indebtedness, create liens, pay dividends, make certain types of investments (including acquisitions), enter into certain types of transactions with affiliates, prepay other indebtedness, sell assets or enter into certain other transactions outside the ordinary course of business, and (ii) require that Gentherm maintain a minimum Consolidated Interest Coverage Ratio and a maximum Consolidated Net Leverage Ratio (based on consolidated EBITDA for the applicable trailing four fiscal quarters) as of the end of any fiscal quarter. As of June 30, 2023, the Company was in compliance with the terms of the Second Amended and Restated Credit Agreement.

Finance Leases

As of June 30, 2023 and December 31, 2022, there was $0.9 million and $1.1 million, respectively, of outstanding finance leases.

Other Sources of Liquidity

The Company is party to receivable factoring agreements with unrelated third parties under which we can sell receivables for certain account debtors, on a revolving basis, subject to outstanding balances and concentration limits. The receivable factoring agreements are transferred in their entirety to the acquiring entities and are accounted for as a sale. Some of the agreements, including those assumed through the acquisition of Alfmeier, have deferred purchase price arrangements. As of June 30, 2023, there were $2.5 million available under the receivable factoring agreement.

Material Cash Requirements

The Company continues to enter into agreements with suppliers to reserve the right to purchase certain semiconductor chips over periods of 12-24 months. As of June 30, 2023, the Company’s total commitments for these semiconductor chip agreements was $34.6 million. See Note 7, “Commitments and Contingencies” to the consolidated condensed financial statements included in this Report for additional information.

Except as described above, there have been no material changes in our cash requirements since December 31, 2022, the end of fiscal year 2022. See Part II, Item 7 “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 for additional information regarding our material cash requirements.

Effects of Inflation

The automotive component supply industry has historically been subject to inflationary pressures with respect to materials and labor. Beginning in 2021 and continuing through 2023, the industry has experienced inflationary cost increases in certain materials and components, labor and transportation. Although the Company has developed and implemented strategies to mitigate the impact of higher material component costs and transportation costs, these strategies, together with commercial negotiations with Gentherm's customers and suppliers have not fully offset to date and may not fully offset our future cost increases. Such inflationary cost increase may increase the cash required to fund our operations by a material amount.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our consolidated condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. For discussion of our significant accounting policies, see Note 2, “Summary of Significant Accounting Policies” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022. There have

37

been no significant changes in our critical accounting policies or critical accounting estimates during the three months ended June 30, 2023. We are not presently aware of any events or circumstances that would require us to update our estimates, assumptions or revise the carrying value of our assets or liabilities, except for the impairment of the Medical segment goodwill. See Note 3, “Restructuring and Impairments” to the consolidated condensed financial statements included in this Report for additional information. Our estimates may change, however, as new events occur and additional information is obtained. As a result, actual results may differ significantly from our estimates, and any such differences may be material to our financial statements.

Recent Accounting Pronouncements

There are no new accounting pronouncements applicable to the Company as of June 30, 2023.

38

ITEM 3. QUANTITATIVE AND QUALITATI VE DISCLOSURES ABOUT MARKET RISK

The Company is exposed to various market risks including, but not limited to, changes in foreign currency exchange rates, changes in interest rates and price fluctuations of certain material commodities such as copper. Market risks for changes in interest rates relate primarily to the Company's debt obligations under the Second Amended and Restated Credit Agreement. Foreign currency exchange risks are attributable to sales to foreign customers and purchases from foreign suppliers not denominated in a location’s functional currency, foreign plant operations, intercompany indebtedness, acquisitions denominated in foreign currencies, intercompany investments and include exposures to the Euro, Mexican Peso, Canadian Dollar, Hungarian Forint, North Macedonian Denar, Ukrainian Hryvnia, Japanese Yen, Chinese Renminbi, Korean Won, Czech Koruna and Vietnamese Dong.

The Company regularly enters into derivative contracts with the objective of managing its financial and operational exposure arising from these risks by offsetting gains and losses on the underlying exposures with gains and losses on the financial instruments used to hedge them. The decision of whether and when to execute derivative financial instruments, along with the duration of the instrument, may vary from period to period depending on market conditions, the relative costs of the instruments and capacity to hedge. The duration is linked to the timing of the underlying exposure, with the connection between the two being regularly monitored. The Company does not enter into derivative financial instruments for speculative or trading purposes. Some derivative contracts do not qualify for hedge accounting; for other derivative contracts, we elect to not apply hedge accounting.

The Company’s designated hedging relationships are formally documented at the inception of the hedge, and hedges must be highly effective in offsetting changes to future cash flows on hedged transactions both at the inception of a hedge and on an ongoing basis to be designated for hedge accounting treatment. For derivative contracts that can be classified as a cash flow hedge, the effective portion of the change in the fair value of the derivative is recorded to Accumulated other comprehensive loss in the consolidated condensed balance sheets. When the underlying hedge transaction is realized, the gain or loss included in Accumulated other comprehensive loss is recorded in earnings in the consolidated condensed statements of (loss) income on the same line as the gain or loss on the hedged item attributable to the hedged risk. The Company records the ineffective portion of foreign currency and copper commodity hedging instruments, if any, to Cost of sales, and the ineffective portion of interest rate swaps, if any, to Interest expense, net in the consolidated condensed statements of (loss) income. Cash flows associated with derivatives are reported in Net cash provided by (used in) operating activities in the consolidated condensed statements of cash flows.

Information related to the fair values of all derivative instruments in our consolidated condensed balance sheet as of June 30, 2023 is set forth in Note 9, “Financial Instruments” in the consolidated condensed financial statements included in this Report.

Interest Rate Sensitivity

The table below presents principal cash flows and related weighted average interest rates by expected maturity dates for each of the Company’s debt obligations, excluding finance leases. The information is presented in U.S. dollar equivalents, which is the Company’s reporting currency.

|  | Expected Maturity Date |
|  | 2023 |  |  | 2024 |  |  | 2025 |  |  | 2026 |  |  | 2027 |  |  | 2028 |  |  | Total |  |  | Fair Value |
Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Long-Term Debt: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Variable rate |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 217,000 |  |  | $ | — |  |  | $ | 217,000 |  |  | $ | 217,000 |
Variable interest rate as of June 30, 2023 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6.58 | % |  |  |  |  |  | 6.58 | % |  |  |
Fixed rate |  | $ | 269 |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | — |  |  | $ | 269 |  |  | $ | 269 |
Fixed interest rate |  |  | 3.90 | % |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.90 | % |  |  |

Based on the amounts outstanding as of June 30, 2023, a hypothetical 100 basis point change (increase or decrease) in interest rates would impact annual interest expense by $2.2 million. To hedge the Company's exposure to interest payment fluctuations on a portion of these borrowings, we entered into a floating-to-fixed interest rate swap agreement with a notional amount of $100.0 million.

39

Exchange Rate Sensitivity

The table below provides information about the Company’s foreign currency forward exchange rate agreements that are sensitive to changes in foreign currency exchange rates. The table presents the notional amounts and weighted average exchange rates by expected (contractual) maturity dates for each type of foreign currency forward exchange agreement. These notional amounts generally are used to calculate the contractual payments to be exchanged under the contract.

|  | Expected Maturity or Transaction Date |  |  |  |  |  |  |
Anticipated Transactions and Related Derivatives |  | 2023 |  |  | 2024 |  |  | 2025 |  |  | Total |  |  | Fair Value |
USD Functional Currency |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forward Exchange Agreements: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
(Receive MXN / Pay USD) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total contract amount |  | $ | 27,831 |  |  | $ | 27,030 |  |  | $ | — |  |  | $ | 54,861 |  |  | $ | 9,380 |
Average contract rate |  |  | 20.48 |  |  |  | 21.09 |  |  |  | — |  |  |  | 20.78 |  |  |  |

The table below presents the potential gain and loss in fair value for the foreign currency derivative contracts from a hypothetical 10% change in quoted currency exchange rates.

|  | June 30, 2023 |  |  | December 31, 2022 |
Exchange Rate Sensitivity |  | Potential loss in fair value |  |  | Potential gain in fair value |  |  | Potential loss in fair value |  |  | Potential gain in fair value |
Forward Exchange Agreement:(Receive MXN / Pay USD) |  | $ | 5,863 |  |  | $ | 7,165 |  |  | $ | 3,999 |  |  | $ | 4,888 |

40

ITEM 4. CONTROLS AND PROCEDURES

(a) Evaluation of Disclosure Controls and Procedures

Management of the Company, under the supervision and with the participation of the Chief Executive Officer and the Chief Financial Officer, carried out an evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of June 30, 2023. As defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (as amended, the “Exchange Act”), disclosure controls and procedures are controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported on a timely basis, and that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon this evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2023.

(b) Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal control over financial reporting during the three months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

41

PART I I OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

We are subject to litigation from time to time in the ordinary course of business, however there is no material pending litigation to which we are a party and no material legal proceeding was terminated, settled or otherwise resolved during the three months ended June 30, 2023.

ITEM 1A. RISK FACTORS

The Company’s risk factors have not materially changed from those previously disclosed in Part 1, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022. You should carefully consider the risks and uncertainties described therein.

ITEM 2. UNREGISTERED SALES OF EQUI TY SECURITIES AND USE OF PROCEEDS

Issuer Purchases of Equity Securities During Second Quarter 2023

Period |  | (a) Total Number of Shares Purchased |  |  | (b) Average Price Paid Per Share |  |  | (c) Total Number of Shares Repurchased as Part of Publicly Announced Plans or Programs |  |  | (d) Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs (1) |
April 1, 2023 to April 30, 2023 |  |  | — |  |  | $ | — |  |  |  | — |  |  | $ | — |
May 1, 2023 to May 31, 2023 |  |  | 167,406 |  |  | $ | 59.71 |  |  |  | 167,406 |  |  | $ | 110,007 |
June 1, 2023 to June 30, 2023 |  |  | — |  |  | $ | — |  |  |  | — |  |  | $ | — |

(1)
In December 2020, the Board of Directors authorized a stock repurchase program (the “2020 Stock Repurchase Program”). Under the 2020 Stock Repurchase Program, the Company is authorized to repurchase up to $150.0 million of its issued and outstanding common stock over a three-year period, expiring December 15, 2023. The authorization of this stock repurchase program does not require that the Company repurchase any specific dollar value or number of shares and may be modified, extended or terminated by the Company’s Board of Directors at any time.

ITEM 5. OTHER INFORMATION

Trading Plans – Directors and Section 16 Officers

During the three months ended June 30, 2023, none of the Company's directors or Section 16 officers adopted or terminated (i) any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or (ii) any n on-Rule 10b5-1 trading arrangement.

42

ITEM 6. EXHIBI TS

Exhibits to this Report are as follows:

|  |  |  |  |  | Incorporated by Reference
Exhibit Number |  | Exhibit Description |  | Filed /Furnished Herewith |  | Form |  | Period Ending |  | Exhibit / Appendix Number |  | Filing Date
3.1 |  | Second Amended and Restated Articles of Incorporation of Gentherm Incorporated |  |  |  | 8-K |  |  |  | 3.2 |  | 3/5/18
3.2 |  | Amended and Restated Bylaws of Gentherm Incorporated |  |  |  | 8-K |  |  |  | 3.1 |  | 5/26/16
10.1* |  | Gentherm Incorporated 2023 Equity Incentive Plan |  |  |  | 8-K |  |  |  | 10.1 |  | 5/18/23
10.2* |  | Form of Performance Stock Unit Award Agreement under the Gentherm Incorporated 2023 Equity Incentive Plan |  |  |  | 8-K |  |  |  | 10.2 |  | 5/18/23
10.3* |  | Form of Restricted Stock Unit Award Agreement under the Gentherm Incorporated 2023 Equity Incentive Plan |  |  |  | 8-K |  |  |  | 10.3 |  | 5/18/23
10.4* |  | Form of Restricted Stock Award Agreement (Director) under the Gentherm Incorporated 2023 Equity Incentive Plan |  |  |  | 8-K |  |  |  | 10.4 |  | 5/18/23
31.1 |  | Section 302 Certification – CEO |  | X |  |  |  |  |  |  |  |
31.2 |  | Section 302 Certification – CFO |  | X |  |  |  |  |  |  |  |
32.1** |  | Section 906 Certification – CEO |  | X |  |  |  |  |  |  |  |
32.2** |  | Section 906 Certification – CFO |  | X |  |  |  |  |  |  |  |
101.INS |  | Inline XBRL Instance Document – The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. |  | X |  |  |  |  |  |  |  |
101.SCH |  | Inline XBRL Taxonomy Extension Schema Document. |  | X |  |  |  |  |  |  |  |
101.CAL |  | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.DEF |  | Inline XBRL Taxonomy Extension Definition Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.LAB |  | Inline XBRL Taxonomy Extension Label Linkbase Document. |  | X |  |  |  |  |  |  |  |
101.PRE |  | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |  | X |  |  |  |  |  |  |  |
104 |  | Cover Page Interactive Data File (embedded within the Inline XBRL document contained in Exhibit 101) |  | X |  |  |  |  |  |  |  |

* Indicates management contract or compensatory plan.

** Documents are furnished not filed.

43

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

| Gentherm Incorporated
| /s/ P HILLIP E YLER
| Phillip Eyler
| President and Chief Executive Officer
| (Principal Executive Officer)
| Date: August 1, 2023

| /s/ M ATTEO A NVERSA
| Matteo Anversa
| Executive Vice President, Chief Financial Officer and Treasurer
| (Principal Financial Officer)
| Date: August 1, 2023

44